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ABSTRACT
Immunoassays of Potential Cancer Biomarkers in Microfluidic Devices
Jayson Virola Pagaduan
Department of Chemistry and Biochemistry, BYU
Doctor of Philosophy
Laboratory test results are important in making decisions regarding a patient’s diagnosis
and response to treatment. These tests often measure the biomarkers found in biological fluids
such blood, urine, and saliva. Immunoassay is one type of laboratory test used to measure the
level of biomarkers using specific antibodies. Microfluidics offer several advantages such as
speed, small sample volume requirement, portability, integration, and automation. These
advantages are motivating to develop microfluidic platforms of conventional laboratory tests. I
have fabricated polymer microfluidic devices and developed immunoassays on-chip for potential
cancer markers.
Silicon template devices were fabricated using standard photolithographic techniques.
The template design was transferred to a poly(methyl methacrylate) (PMMA) piece by hot
embossing and subsequently bonded to another PMMA piece with holes for reservoirs. I used
these devices to perform microchip immunoaffinity electrophoresis to detect purified
recombinant thymidine kinase 1 (TK1). Buffer with 1% methylcellulose acted as a dynamic
coating that minimized nonspecific adsorption of protein and as sieving matrix that enabled
separation of free antibody from antibody-TK1 complexes. Using this technique, I was able to
detect TK1 concentration >80 nM and obtained separation results within 1 minute using a 5 mm
effective separation length.
Detection of endogenous TK1 in serum is difficult because TK1 is present at the pM
range. I compared three different depletion methods to eliminate high abundance
immunoglobulin and human serum albumin. Cibacron blue columns depleted abundant protein
but also nonspecifically bound TK1. I found that ammonium sulfate precipitation and
IgG/albumin immunoaffinity columns effectively depleted high abundance proteins. TK1 was
salted out of the serum with saturated ammonium sulfate and still maintained activity.
To integrate affinity columns in microfluidic devices, I have developed a fast and easy
strategy for initial optimization of monolith affinity columns using bulk polymerization of
multiple monolith solutions. The morphology, surface area, and porosity, were qualitatively
assessed using scanning electron microscopy. This method decreased the time, effort, and
resources compared to in situ optimization of monoliths in microfluidic devices. This strategy
could be used when designing novel formulations of monolith columns.

I have also integrated poly(ethylene glycol dimethacrylate-glycidyl methacrylate)
monolith affinity columns in polymer microfluidic devices to demonstrate the feasibility of
extracting human interleukin 8 (IL8), a cancer biomarker, from saliva. Initial results have shown
that the affinity column (~3 mm) was successfully integrated into the devices without prior
surface modification. Furthermore, anti-IL8 was immobilized on the surface of the monolith.
Electrochromatograms showed that 1 ng/mL of IL8 can be detected when in buffer while 10
ng/mL was detected when IL8 was spiked in saliva.
Overall, these findings can be used to further develop immunoassays in microfluidic
platforms, especially for analyzing biological fluids.
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CHAPTER 1: INTRODUCTION∗
1.1

ADVANTAGES

OF

MICROCHIP

ELECTROPHORESIS

FOR

CLINICAL

MARKER ANALYSIS
The push for improved health care is increasing the need to develop diagnostic tools that are
cost-effective, reliable, and fast. Lack of resources and expertise in many developing countries
limits their ability to perform straightforward clinical diagnostic tests. On the other hand,
developed countries often have a backlog of tests that results in longer waiting times for results
to be dispensed to the physicians and ultimately to the patients. A causative factor in these
problems with clinical diagnostics is that they are done using conventional benchtop analysis
platforms that are effective yet slow, lab-bound, labor intensive, and consume large volumes of
reagents and expensive samples. Because of some of the disadvantages of conventional methods,
researchers adapted photolithography and chemical etching techniques from the microelectronics
industry to make microfluidic analysis systems starting in the early 1990s.1 The goal of this
chapter is to describe advances in microchip electrophoresis over the last 5 years in the analysis
of clinically relevant biomarkers, including lipids, carbohydrates, nucleic acids, and proteins. I
further highlight the advantages over conventional benchtop techniques offered by microchip
electrophoresis in the analyses of clinical samples.
Commonly used disease diagnostic tools process complex bodily fluids.2,3 Microchip
electrophoresis offers advantages for clinical analysis like speed, small sample volumes, low
power, and integration of multiple sample manipulation processes into a compact format.4 The
∗

Sections 1.1 and 1.4 adapted with permission from Pagaduan, J.; Sahore, V.; Woolley, A.T. Anal. Bioanal. Chem.
2015, accepted for publication.
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manufacturing procedure for these devices is compatible with well-established semiconductor
processing techniques. Moreover, microchip electrophoresis systems are compatible with pointof-care analysis that can be performed by semi-skilled workers in resource-limited locations.5, 6
1.2 MICROFLUIDIC DEVICE FABRICATION
The techniques used to fabricate the microfluidic devices were adapted from the methods
previously developed in the microelectronics industry.7 A schematic of the procedure for
template and device fabrication is illustrated in Figure 1.1. Briefly, a <100> silicon wafer was
thermally oxidized before spin coating with positive photoresist. The coated silicon wafer was
exposed to UV light through a photomask containing the channel design. The wafer was
developed to remove the exposed photoresist and then etched in 10% buffered HF solution to
remove the oxide layer. Further etching with 40% aqueous KOH was done to obtain ~20-µm
height features.

The fluidic design was hot embossed onto 1.5 mm thick poly(methyl

methacrylate) (PMMA) sheets by sandwiching the template and PMMA between glass and
copper plates held by C-clamps. The assembly was held in a convection oven for 20 minutes at
110 °C. Then a 3.0 mm thick PMMA piece with precut holes for reservoirs was used as a cover
plate. The two pieces were thermally bonded in an assembly in a convection oven at 138 °C for
27 minutes.

2

Figure 1.1 Fabrication of PMMA microfluidic devices.

1.3 MICROCHIP ELECTROPHORESIS
1.3.1 Introduction
Microchip electrophoresis (ME) is the miniaturization of capillary electrophoresis that
was introduced in the early 1990’s.1 As described in section 1.2, ME devices are made using
microfabrication techniques used by the electronics industry. The high surface area to volume
ratio effectively dissipates Joule heating making it possible to use higher voltages in ME.8 The
simplicity of ME plus its further advantages that include fast analysis, multiplex separation, low
sample volume, low cost, and portability resulted in increased interest in applying this
technology for point-of-care analysis.9
1.3.2 Theory of Electrophoresis
Electrophoresis is the movement of charged analytes due to the influence of an applied
potential difference. Electrophoretic flow and electroosmotic flow (EOF) are the two phenomena
3

observed in typical capillary electrophoresis that affect the migration velocity, v, of an analyte.
The resulting migration phenomenon can be mathematically represented in equation 1.1,10
(1.1)
where µe is the electrophoretic mobility of the analyte, µeof is the EOF, and E is the electric field.
The electrophoretic mobility is governed by the charge to mass ratio of the analyte expressed in
equation 1.2,10
(1.2)
where q is the charge of the analyte, E is the field strength (V/cm), η is the viscosity of the fluid
and r is the radius, which is related to the mass of the analyte. The mass of an analyte is constant
so manipulation of its charge by the buffer pH is the easiest way to change the separation of
analytes with the same mass.
Surface channels with a net charge attract free ions of the opposite charge to create a thin
Debye layer of mobile charges next to the charged surface and the potential difference in this
double layer is called the zeta potential.11 When an external field is applied, the fluid in this
charged Debye layer is moved resulting in bulk fluid flow. This uniform velocity is described in
the Helmholtz-Smoluchowski formula:12
(1.3)
Here, ε is the dielectric constant of the fluid, E is the applied electric field, and ζ is the zetapotential at the liquid solid interface. Figure 1.2 illustrates the formation of the double layer near
a negatively-charged channel wall.

4

Figure 1.2 Direction of EOF with a negatively charged channel wall.

EOF is also affected by the pH, composition and concentration of background electrolyte;
therefore, it is susceptible to changes that can alter the EOF during an experiment. However,
when EOF is stabilized, it can reduce electrokinetic sample injection bias and make it possible to
analyze cations, anions and neutral molecules simultaneously. The uniform plug flow profile
produced by EOF that results in reduced sample dispersion is an important contrast to pressure
driven flow.
1.3.3 Device Operation and Detection
Several injection methods are utilized in ME. Electrokinetic injection is commonly used
because of its simplicity and no need for moving parts. This method uses an electric field to
manipulate the direction of sample flow.13 The two most common modes of electrokinetic
injections are pinched and gated.14 Pinched injection (see figure 1.3) provides an accurate, welldefined volume of sample plug and provides high separation efficiency. However, this technique
limits the sample volume by the dimension of the intersection, which can be detrimental for
5

analysis of very dilute samples.15 In gated injection, sample volume can be increased by
changing the injection time while sample volume does not change with time in pinched
injection.16 Gated injection, like pinched injection, also produces injection bias due to the
differences in the electrophoretic mobilities of analytes.17

Figure 1.3 Schematic of voltage configuration for pinched injection. SR sample reservoir, BR buffer
reservoir, WR waste reservoir, SW separation waste.

Laser induced fluorescence (LIF) detection was used in the experiments described in the
succeeding chapters. Figure 1.4 illustrates a simplified schematic of the detection system. The
diode laser excites the fluorescent molecules as they pass through the detection point. The
emitted light passes through the dichroic mirror and is detected by the photomultiplier tube. The
6

quantity of photons that reach the detector is converted to an electrical signal that is then
processed by LabView software on a computer.

Figure 1.4 Schematic of laser induced fluorescence detection system.

1.4 RECENT ADVANCES IN MICROCHIP ELECTROPHORESIS OF BIOMARKERS
1.4.1 Introduction
Clinical diagnostics need to detect biological molecules that are disease indicators
(biomarkers) in complex bodily fluidic samples. Thousands of biomarkers have been reported in
literature, and nearly 100 of these are used in regular clinical practice.18 ME is a promising
technology that is being developed and tested for biomarker detection in clinical samples such as
urine, serum, cerebrospinal fluid, and saliva. Application of different separation principles, such
as isotachophoresis, capillary zone electrophoresis and micellar electrokinetic chromatography in
7

ME has been explored, resulting in improved separations. Use of different detection methods
such as UV absorption, fluorescence, chemiluminescence, and electrochemistry allows analyses
of different biomarkers. The following sections discuss various clinical biomarkers tested using
ME including lipids, carbohydrates, nucleic acids, and proteins.
1.4.2 Lipids
In this section I discuss ME methods for assaying different classes of lipids including
lipoproteins, cholesterol and phospholipid biomarkers. Lipoproteins are macromolecular
complexes of lipids and globular proteins held together by hydrophobic and electrostatic
interactions. Lipoproteins are involved in transport of lipids; and atherosclerosis, coronary heart
disease, liver dysfunction and cancer are all associated with lipoproteins.19-22 These complexes
can be classified as high density lipoprotein (HDL), low density lipoprotein (LDL) or very low
density lipoprotein (VLDL). Common methods of lipoprotein analysis are ultracentrifugation,
enzymatic assays, nuclear magnetic resonance, and size exclusion chromatography.23-25
Cholesterol is an important marker for assessing risk for cardiovascular conditions such as
atherosclerosis and hypertension. Total cholesterol detection using ME in poly(dimethylsiloxane)
(PDMS) devices was reported by Ruecha et al.26 Amperometric detection was used to quantify
the total cholesterol by monitoring the reaction of cholesterol with cholesterol oxidase enzyme.
Separation and detection of cholesterol and an interfering species (ascorbic acid) using ME
resulted in reliable quantitation. The detection limit for cholesterol in serum without sample
preparation was 1 nM, well below clinical levels, and the limit of quantitation was 1 µM. Sample
stacking was achieved by diluting serum in water instead of separation buffer, and analysis took
less than 100 seconds.
8

Fractionation into subclasses of lipoproteins can give a better understanding of the
physiological condition of a patient. Wang et al.27 described ME separation of two protein
subclasses (large buoyant LDL and small, dense LDL) using a PDMS/glass microfluidic device.
Modifying the channel surface with β-D-maltoside and adding hydroxypropyl cellulose in the
running buffer achieved optimum separation. This combination of surface modification and
sieving matrix enabled separation of fluorescently labeled HDL and the two LDL subclasses
within 3 minutes. The optimized separation conditions were tested for the analysis of serum of
patient before and after treatment with atorvastatin. The results showed a significant decrease in
the quantity of short, dense LDL after treatment, indicating a possible prognostic application of
ME.
Phospholipids are susceptible to reactive oxygen species (ROS); indeed, peroxidation of
phospholipid arachidonyl residues by ROS generates prostaglandins, a complex group of
biomarkers found in various biofluids.28 Isoprostanes, a subset of prostaglandins, are a ROS
indicator in cardiovascular disease.29 Because lipids tend to aggregate in aqueous solutions
typically used for electrophoretic separations, Gibson and Bohn30 described a method for
characterization of lipids using non-aqueous ME that could be applied to lipid biomarker
detection. With their buffer system composed of a tetraalkylammonium salt in Nmethylformamide, they observed that the separation of 3 model lipids depended on the voltage
and timing of the injection pulse, the background electrolyte concentration, and the electric field
strength. As expected, the number of theoretical plates increased with electric field and
decreased with background electrolyte concentration. Separation of lipid mixtures was achieved
with high resolution (>5) and theoretical plate counts in excess of 7.7 x 106 plates/m.
9

These recent results show that ME is an attractive alternative to traditional methods such as
ultracentrifugation for lipid determination. Such microchip methods offer fast analysis, low
sample consumption, and sufficient sensitivity for clinical application.
1.4.3 Carbohydrates
Glycosylation, the addition of a carbohydrate moiety, is a post-translational modification that
affects the function of proteins; for example, carbohydrates expressed on the surface of cells vary
in structural complexity. Understanding the significance and the function of these modifications
requires robust methods for their characterization and quantitation. The most common method of
analysis of glycoproteins is by mass spectrometry. Glycoproteins are often treated enzymatically
to release the polysaccharides, which can be further cleaved into monosaccharides.31,

32

Mass

spectrometry is a powerful tool for carbohydrate analysis but is less well suited for point-of-care
diagnostics. ME is an alternative to mass spectrometry that is a much better fit with point-of-care
assays.
Mitra et al.33 described electrophoretic analysis of N-glycans from RNase B and
glycoproteins in the blood sera of an ovarian cancer patient and a disease-free individual using
glass microchips with asymmetrically tapered turns that reduced dispersion. The plate count was
940,000 for a 36-cm channel and 600,000 for a 22-cm channel. The microchip devices were used
to analyze both native and desialylated N-glycans. Isomer separation of mannose 7 and mannose
8 was observed in the longer (36 cm) but not in the shorter (22 cm) channels. The
asymmetrically tapered turn geometry improved over the spiral geommetry reported earlier by
Zhuang et al.34 for separation of N-glycans that resulted in 400,000 to 655,000 plates. In both
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designs, increasing the electric field from 75 V/cm to 1250 V/cm resulted in an increase in
resolution, as well as a reduction of the analysis time.
Monosaccharides with similar structure, molecular weight and electric charge are difficult to
separate. Nagata et al.35 demonstrated the use of a discontinuous pH buffer system for the
separation of neutral and amino monosaccharides. Stacking was achieved by using pH 6.0 borate
solution for the sample buffer and pH 9.3 Tris-borate for the separation buffer. The sensitivity
was improved by a factor of 65 compared to results in a continuous buffer system.
ME offers a simple and potentially less costly alternative to mass spectrometric analysis of
carbohydrates, which could increase understanding of glycosylation that is implicated to
different diseases. Importantly, ME allows the complexity of carbohydrate structure to be
effectively resolved by manipulating the buffer conditions and geometry of the microfluidic
devices.
1.4.4 Nucleic Acids
DNA and RNA analyses are important in disease diagnosis, forensics, and drug screening.
Traditionally, fragments of nucleic acids are amplified through PCR and then analyzed. Reagents
used in these processes can be expensive; therefore miniaturization of nucleic acid analysis is
beneficial for clinical diagnostics. Sample preparation, PCR and electrophoresis can also be
integrated using microfluidics resulting in a real lab on a chip.
Clinical genotyping is becoming important especially with the paradigm shift toward
personalized medicine.36 For example, warfarin is a common oral anticoagulant medication that
is one of the top 20 most commonly prescribed medications in the US; however, the dosage of
this drug to obtain a therapeutic effect varies among individuals.37 Proper dosage is vital because
11

an incorrect dosage can have adverse effects and in extreme cases be fatal. Genotyping for
warfarin dosage using a single PCR reaction and subsequent ME was reported by Poe et al.38 By
using microchip PCR, the amplification time was reduced to 30 minutes from 45 minutes with
benchtop PCR, and the complete assay, combining PCR with ME, took only 60 minutes. The
assay determined the patient’s genotype using a tetraprimer amplification refractory mutation
system in a single reaction. This reduction in reagent and sample consumption using
microfluidics could enable low-cost genotyping for warfarin and other genotype-sensitive
medications.
Multiplex PCR is commonly used to quickly detect aberrations in DNA sequences of large
genes, such as short tandem repeat DNA sequences that have a repetitive unit of 1-6 base pairs
and can be used to study polymorphisms or mutation rates important for forensic analysis and
identification of genetic diseases.39 Conventionally, PCR products from multiplex PCR are
probed using a Southern blot that can take several hours to yield results. Also, in some cases
quantitative analysis of the PCR products is necessary for a diagnosis, which is difficult to
achieve via Southern blotting. Le Roux et al.40 developed a prototype of an integrated microchip
for multiplex PCR amplification and electrophoresis. They showed baseline separation of a 10
allele ladder with comparable separation results to a conventional benchtop PCR system. The
valve less plastic microchip devices they used had an effective separation length of 7 cm. Under
optimized separation conditions they were able to discriminate short tandem repeats having twobase or single-base differences. They also showed consistency of results over time and even
when devices were transferred from one laboratory to another. These results suggest the
possibility of using portable integrated PCR-ME devices without the need to calibrate before use.
12

These integrated microchips for multiplex PCR could be used in clinical analysis or personalized
medicine.
1.4.5 Proteins
Enzyme linked immunosorbent assay and western blot analysis are commonly used methods
as serological tests for different diseases such as HIV and hepatitis B. However, these methods
take hours and require multiple processing steps. Furthermore, traditional on-plate assay or
membrane analysis requires reagents that increase the cost. In western blot analysis, membrane
processing is a slow step that may take at least one hour. An integrated ME system with western
blotting developed by Jin et al.41 reduced the time to 22-32 min for a complete immunoassay.
They tested this system on a number of proteins, including actin, carbonic anhydrase and
lysozyme. Proteins were detected at concentrations as low as 10 nM. Furthermore, with an
increase to 9 samples in one membrane, the analysis time decreased to 6 min/sample. Integrating
multiple channels in the microfluidic devices could result in still higher throughput analyses.
Single-cell protein analysis is an important step to elucidate cell signaling and determine cell
heterogeneity, for example in drug discovery and cancer studies.42 Hughes et al.43 demonstrated
single-cell western blotting in microfluidic devices made from a microscope slide coated with a
thin, photoactive polyacrylamide gel. Cell lysis and western blotting were performed in situ.
Proteins released from lysed neural stem cells were electrophoresed and immobilized on the
polyacrylamide gel before probing with fluorescent antibodies for multiple differentiation
markers. Kang et al.44 further tested the application of these devices to study the heterogeneity of
cells within a tumor and assess the response of tumor cells to a chemotherapeutic drug. The
whole system consisted of single cell imaging, cell lysis, polyacrylamide gel electrophoresis, UV
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crosslinking of proteins onto the gel and target probing with fluorescent antibodies. This system
allowed correlation of cell phenotype to proteomic profile. They tested this set-up to study drug
resistance of a glioblastoma cell line and were able to analyze up to 30 cells/min. This approach
may become a valuable tool to identify small populations of drug resistant cells within a tumor
that are currently difficult to identify using conventional methods.
One of the agreed upon hallmarks of etiology of Alzhiemer’s disease is the accumulation of
β-amyloid peptides in amyloid plaques found in cerebrospinal fluid (CSF), blood and urine.45
However, detection of these peptides in blood and urine is more difficult because their
concentrations are 10-100 times smaller than in CSF (1 to 10 ng/mL). Mohamadi et al.46
described a two-step microchip analysis of five different β-amyloid peptides from CSF in PDMS
devices. To enrich the target analytes, they performed immunocapture in a microchip and labeled
the eluted analytes with fluorescent dye. They found that β-amyloid 42 could be detected by ME,
but baseline separation of the five β-amyloids was not successfully achieved in purified samples
or CSF samples. However, analysis of markers in CSF was obtained within 150 seconds. They
also found that preconcentration of CSF was a necessary step to be able to detect the amyloid
peptides. This detection method shows a promising application of ME in detecting Alzheimer’s
disease.
Haptoglobin (Hp) binds to hemoglobin released by dead red blood cells, and this complex is
then transported to the liver for recycling. Thus, Hp testing is often done to determine how fast
red blood cells are destroyed. Common methods for detecting haptoglobin phenotypes are based
on electrophoretic separation using a polyacrylamide gel, but this method requires both
separation and staining for detection.47 Different Hp phenotypes have recently been shown to
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have association with diseases: the Hp 2-2 phenotype is correlated with higher risk of developing
refractory hypertension and schizophrenia;48,

49

in contrast, Hp 2-2 appears to have protective

benefit while Hp 1-1 increases the risk for cervical cancer. Huang et al.50 tested ME for Hp
phenotyping and showed that fluorescently labeled Hp from a liver cancer patient’s serum had
lower Hp 2-2 levels compared to normal serum. Hp was only clearly detected in serum upon
depletion of the abundant human serum albumin and immunoglobulins. The analysis of
processed serum took only 150 s by ME, while 400 s were needed for conventional capillary
electrophoresis. Low cost, short separation time and sufficient sensitivity are the advantages of
ME for the detection of diseases associated with haptoglobin.
In clinical diagnostics, selective detection of target biomarkers in complex biological samples
is necessary for an accurate diagnosis. Often, immunoaffinity columns are utilized to purify and
concentrate biomarkers, especially for low abundance ones.51 Biological samples such as CSF
and tissue biopsies are typically obtained only in limited amounts and also require sample
preparation before analysis. Thus, developing microfluidic analysis of quantity-limited samples
would be advantageous.
As one example, dermatological diseases like atopic dermatitis may require lesion biopsy and
immunochemical analysis to determine if the lesion is caused by infiltrating neutrophils leading
to clinical inflammation or by infiltrating T-cells suggesting prolonged associated inflammation.
Kalish et al.52 analyzed 6 µm diameter frozen biopsy sections from atopic dermatitis lesions for
the presence of 5 chemokines by using an integrated microchip immunoaffinity capillary
electrophoresis system. Only 200 nL of tissue homogenate with a total protein concentration of 1
µg/mL was used for analysis. The immunoaffinity disks allowed specific extraction of
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biomarkers and the succeeding ME separation enabled quantification and confirmation of
specificity. Quantifying the chemokines from the biopsy allowed the two types of clinically
relevant allergic skin lesions to be distinguished. This method is advantageous over traditional
immunoassays, because it uses a small sample volume so it is well suited for detection of disease
biomarkers from skin biopsies. The integrated device demonstrates the promise of analyzing
complex tissue homogenates.
ME has been combined with several common biochemical analysis methods such as western
blot and immunoaffinity. Biomarkers from varied, complex specimens can be analyzed using
ME, providing lower sample and reagent consumption as attractive advantages for clinical
analysis of limited samples.
1.4.6 Conclusions about applications of microchip electrophoresis to biomarkers
ME has been demonstrated to be applicable for analysis of different biomarkers including
lipids, carbohydrates, nucleic acids and proteins. The various materials available for fabricating
microfluidic devices make it possible to use aqueous or non-aqueous buffers suitable for analysis
of different biomarkers. Interfacing with different detection systems also expands the versatility
and sensitivity of ME for various biomarkers. Finally, the relatively simple fabrication of these
devices makes it easy to design layouts that can be adapted to various analyses.
Integration of multiple processes in a single microfluidic device offers totally automated
sample analysis that may be applicable for clinical laboratories and point-of-care diagnostics.
Recognition of the benefits offered by this technology no doubt played a key role in the
development of commercial ME platforms offered by companies such as Agilent, BioRad and
Bio-Techne. However, these commercial systems are still expensive and benchtop, rather than
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point of care. Furthermore, validation of assays for clinically relevant biomarkers is needed for
this technology to be widely used in clinical laboratories or point-of-care diagnostics.
The study and modification of the surface chemistry of materials used for microfluidic
devices should improve control of the physical phenomena that affect electrophoresis and lead to
more reproducible and predictable results. Further characterization of the effects of device
layouts and engineering designs should shed additional light on the effects of channel
dimensions and geometry on fluid dynamics and assays. Advances in fabrication methods can
further decrease the channel dimensions and ease the integration of processes and electronics
needed for automated analysis. Miniaturization and improved packaging of detection systems
such as optical and electrochemical ones would move a step closer to

complete

lab-on-a-chip

systems. Such advances should lead to low-cost, portable, sensitive and fast tools for analyzing
clinical biomarkers from biological fluids or biopsies.
1.5 SURFACE MODIFICATION
1.5.1 Introduction
Surface modification is one of the factors manipulated for target analyte extraction or
improved separation by suppressing non-specific adsorption and modulation of EOF. One of the
challenges in analysis of complex biological samples such as blood is the non-specific adsorption
of proteins on the channel wall. The focus of this section is to briefly discuss stable and dynamic
coatings for surface modifications that demonstrate ability to inhibit nonspecific adsorption and
provide uniform EOF for ME. Doherty et al.53 gave an excellent detailed review on microchannel
wall coatings.
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1.5.2 Methods of surface modification
1.5.2.1 Stable Modification
Stable surface modification with biocompatible layers such as poly(ethylene glycol)
(PEG) reduces nonspecific adsorption of biomolecules. There are four common strategies used in
stable surface modification. Layer-by layer film deposition involves sequential deposition of
polyelectrolyte to modify the surface charge that reduce nonspecific adsorption and resulted in
EOF independent of pH.54 Click chemistry is a covalent modification that results in robust and
selective chemical reactions using azides that has been applied in glass microfluidic devices.55
Atom transfer radical polymerization employs a metal catalyst such as copper to immobilize
hydrophilic polymers on different surfaces.56 Grafting utilizes the active site on the surface of the
channels to covalently bond hydrophilic polymer or ligand on UV-activated microfluidic channel
surfaces.57-59 These modification processes remain stable at varying pH and over multiple runs.
However, the tedious processes employed in stable surface modification spur the exploration of
different dynamic coatings.
1.5.2.2 Dynamic Coating
Polymer microfluidic devices are hindered by the problem of sample adsorption.60 This
non-specific adsorption results in reduced reproducibility and separation efficiency.61 Different
water-soluble surfactants such as sodium dodecyl sulfate (SDS),62 cellulose-based polymers,63
and PEG64 have been used as buffer additives that act as dynamic coatings. Increasing the
concentration of the polymers to their entanglement point can also provide a sieving matrix that
can improve separation efficiency.64-66 The ease of this method decreases the device preparation
time and still produces acceptable separation efficiency and reproducibility.
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1.6 MONOLITHS
Monoliths are a single piece of a porous particle that are widely being studied as solid
supports for liquid chromatography67 and for miniaturized systems such as capillary
electrophoresis and ME.68 The advantages of low back pressure, ease of fabrication, lower dead
volume and faster mass transfer make monoliths an attractive alternative to columns made of
packed beads.69 Monoliths have been developed into affinity columns using various substrates
such as agarose,70 methacrylates,71 and silica.72 Detailed optimization of fabrication processes for
monolithic columns in microchips will be discussed in chapter 4.
1.7 IMMUNOASSAYS
Immunoassays are commonly used in clinical diagnostics and rely on the formation of an
antigen-antibody complex to determine the presence or absence of the antigen of interest. The
principles regarding immunoassays are the same in the traditional 96-well plate enzyme linked
immunosorbent assay (ELISA) (see Figure 1.5) or in the microarray immunoassays. First,
antigens are immobilized on the solid support. Primary antibodies conjugated to enzymes are
used to probe for the presence of antigens. The most commonly used enzyme to visualize bound
antibodies is horseradish peroxidase (HRP). The HRP/peroxide system oxidizes 3,5,3´,5´tetramethylbenzidine (TMB), to 3,5,3´,5´-tetramethylbenzidine diimine, and subsequently the
reaction can be halted by addition of acidic buffer.73
Antibodies contain antigen binding sites (Fab) that bind to specific or multiple epitopes on
the antigen. This complex formation is reversible. According to the law of mass action (see
equation 1.4), at equilibrium, the ratio between the concentration of the product ([complex]) and
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the reactants ([antigen] and [antibody]) is constant. The equilibrium constant, Keq, is equal to the
ratio between the association (ka) and dissociation (kd) rate constants.
(1.4)
From the equation, complex formation can be improved by increasing the concentrations
of the antigen and antibody, or increasing the equilibrium constant; for example, a stronger bond
results in a higher equilibrium constant. The forces that govern the interaction of Fab and epitope
include Van der Waals, electrostatic, ion dipole, and hydrophobic interactions.74 Antigenantibody complex formation is affected by several factors such as pH, temperature, and ionic
strength.

Figure 1.5 Direct ELISA.

The amino acids involved in antigen-antibody interaction can be protonated or
deprotonated depending on their isoelectric point. Extreme pH values induce conformational
changes to the antibody or the antigen that destroy the complementarity of the antigen and
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antibody binding sites.75 The optimum temperature depends on the weak bonds involved in the
interaction as well as the chemical nature of the epitope and the paratope, which is the part of the
Fab region that recognizes the antigen. For example, hydrogen bonds are more stable at low
temperature.76 At increasing temperature, the protein conformation changes and more
hydrophobic regions are exposed; therefore, hydrophobic interaction increases with
temperature.77 Ionic strength, the concentration of ions in a solution, can affect the availability of
the paratopes and epitope to interact due to the interaction of ions with the charged groups of the
proteins. A study on an antibody against blood group antigen D revealed that decreasing the
ionic strength of the buffer resulted in increased rate of association.78 These factors have to be
considered carefully when designing immunoassays, and condition optimization for each
antibody used in an experiment must be done to ensure reliable results.
1.8 CANCER BIOMARKERS
1.8.1 Introduction
Biomarkers are measurable molecular indicators of normal biological processes,
pathological processes or a pharmacological response to a therapeutic agent. Biomarkers are
obtained from tissue samples and biological fluids such as blood, urine, and saliva. For a
biomarker to be accepted for clinical use, several characteristics must be assessed. It should have
high sensitivity, accurately-a high true positive rate, and specificity, accurately-a high true
negative rate. Two potential biomarkers I studied were thymidine kinase 1 (TK1) and interleukin
8 (IL8).
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1.8.2 Thymidine Kinase 1
Thymidine kinase is an enzyme involved in the DNA salvage pathway. There are two
isoenzymes of thymidine kinase, cytosolic TK (TK1) and mitochondrial TK (TK2). TK1 is cellcycle dependent while TK2 is constitutively expressed.79 Thymidine kinase 1 has been reported
to be elevated in serum of cancer patients.80 TK1 activity is regulated by post-transcriptional and
post-translational mechanisms. The precise function of TK1 is still not fully understood since
many TK1 deficient cells grow normally in culture, though research suggests that TK1 is
important for precise fine-tuning of the pool size of dTTP, an allosteric regulator of the
mammalian

ribonucleotide

reductase.79,81

It

also

catalyzes

the

phosphorylation

of

deoxythymidine, coverting it to deoxythymidine monophosphate (dTMP). The monomer of
human TK1 has a reported molecular weight of 25-30 kD and the oligomeric form has a
molecular weight of up to 96 kD.82 It has been found in breast cancer patients that the serum
level of TK1 has no correlation with the TK1 activity,83 and others have reported that different
isoforms of TK1 have different activity.84 Therefore, analysis of TK1 is not straightforward. The
enzymatic activity at different isoforms could be used to better understand the diagnostic value
of TK1 for cancer detection.
1.8.3 Interleukin 8
IL8 is a chemokine associated with chemotaxis and degranulation of neutrophils.85 It
activates multiple signaling pathways downstream of two G-protein coupled receptors, CXCR1
and CXCR2.86 One of the results of the activation of these receptors is the increased activation of
Akt, a serine/threonine-specific protein kinase, which has a role in modulating cell survival,
angiogenesis and cell migration.87 In 2005, IL8 was first reported to be elevated in saliva, 86 pM,
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of oropharyngeal squamous cell carcinoma cases compared to healthy individuals, 30 pM.88
Analysis of biomarkers from saliva could offer a non-invasive solution for routine diagnosis and
would be compatible with point-of-care diagnostics.
1.9 OVERVIEW OF DISSERTATION
The focus of my dissertation is on development of immunoassays for cancer markers in
microfluidic devices. This dissertation is divided into six chapters. In this chapter, I have
discussed microfluidic device fabrication, principles of ME, including operation and detection;
recent advancements in the last five years in ME of potential clinical biomarkers; surface
modification; monolith columns; principles of immunoassays; and cancer biomarkers, TK1 and
IL8.
In chapter 2, I describe development of a microchip immunoassay for detection of
recombinant thymidine kinase 1 in microchip devices. I describe the selection of appropriate
buffer conditions for immune complex formation and separation. I also explore the effects of
different molecular weights of methylcellulose as a dynamic coating and sieving matrix.
Chapter 3 focuses on determining the appropriate protein depletion method to concentrate
low concentrations of endogenous TK1 in serum. Two candidate monoclonal antibodies, mouse
anti-TK1 and rabbit anti-TK1, which both exhibit specificity to purified recombinant TK1, were
tested for binding to endogenous TK1 in cancer and normal serum samples. I verified my results
using several biochemical techniques such as native and denatured western blots, ELISA and
kinase activity assay. The results showed that, under conditions described in the analyses,
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rabbit-TK1 bound to both endogenous and purified recombinant TK1 (pTK1) while the mouseTK1 exhibited detectable binding only to pTK1.
Chapter 4 describes a strategy for optimization of monolith composition using bulk
polymerization and scanning electron microscopy. The addition of Tween-20 in the monolith
solution resulted in more porous monolithic columns that are compatible with electrokinetic
injection and integration with ME. This method allowed multiple monolith solution comparisons
without the need to initially in situ fabricate the monolith in microchip devices as was previously
done. Other students have successfully adapted this process to develop reverse phase monolithic
columns.89, 90
Chapter 5 describes the development of the optimized monolithic columns into affinity
columns. I also detail the processes involved to immobilize active antibody in integrated
monolithic columns. Preliminary results showed the ability of an integrated monolithic column
to extract IL8 from buffer and spiked-saliva samples.
Conclusions and future work will be discussed in Chapter 6.
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CHAPTER 2: MICROCHIP IMMUNOAFFINITY ELECTROPHORESIS OF
ANTIBODY-THYMIDINE KINASE 1 COMPLEX

∗

2.1 INTRODUCTION
Molecular diagnostics focuses on the accurate detection of biochemical markers of
diseases. Often, blood samples are drawn from the patient and biomarkers are measured to
identify the disease state. The usage of biomarkers can be a more effective way of detecting
cancer at an early stage compared to tissue biopsy alone.1 Cancer biomarkers often indicate
disruption of the regular cell-signaling pattern resulting in resistance to cell death, uncontrolled
proliferation, invasion, metastasis, and activation of angiogenesis.2
Thymidine kinase is an important nucleotide salvage pathway enzyme involved
specifically in the conversion of thymidine to thymidine monophosphate.3 There are two types of
thymidine kinase in the cell: thymidine kinase-1 (TK1) is found in the cytosol and is cell cycle
regulated; the other, thymidine kinase-2, is found in the mitochondria and is constitutively
expressed.4 The mechanism of release of TK1 into the serum is not fully understood, but TK1
concentration in serum is higher in cancer patients than in healthy individuals.5-7
Typically, radioimmunoassay is used to detect TK1 activity in serum,8 and enzymelinked immunoassay (ELISA) is used to determine TK1 concentration.5 Previous reports indicate
that TK1 activity and TK1 concentration are not closely correlated.6 Another finding showed that
∗
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TK1 was commonly expressed in its dimeric form and that addition of ATP to the solution
resulted in tetramer formation.9 The tetrameric TK1 also had more catalytic activity than the
dimeric form, which is a possible explanation for the discrepancy in TK1 activity and
concentration in cancer patients.6
A novel antibody that specifically targets TK1 was developed, tested and reported by
O’Neill et al.10 They demonstrated through ELISA, immunohistochemistry and western blot
results that the antibody has the ability to detect purified recombinant TK1 (pTK1) and cytosolic
TK1 in clinical samples. These classical techniques are sensitive (ng/mL to pg/mL); however,
they are time consuming. A possible alternative to detecting TK1 activity (to eliminate the use of
radioactive material) is through determining the quantity of each isoform of TK1 since the
isoforms correlate with enzymatic activity. Development of an inexpensive, fast, and accurate
diagnostic assay for TK1 isoforms and concentration could thus hasten the accurate detection of
disease state.
Microchip electrophoresis has been used in separation of different clinically relevant
biomolecules because it has many advantages over traditional methods such as use of small
sample volumes, fast analysis, low cost, portability and disposability. Virtually all fluorescent
tags used in on-plate immunoassays can be used in microchip electrophoresis to improve
sensitivity if appropriate laser wavelengths and filters are also incorporated in the detection
system. Microchip electrophoresis can be high throughput by changing the design to include
multiple lanes but still maintain low sample and reagent consumption and faster analysis
compared

to

on-plate

immunoassay.11

Integration

of

photopolymerized

cross-linked

polyacrylamide gels in microfluidic devices has been used for separation of immune
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complexes.12, 13 As an alternative to photopolymerization of gels, buffers with cellulose-based
polymers or linear polyacrylamide as dynamic coatings and sieving matrices have been
developed.14-16 Different cellulose sieving matrices were successfully used for genomic and
proteomic analysis.17 The ability of methylcellulose to effectively suppress electroosmotic flow
and stabilize the pH gradient allowed efficient isoelectric focusing on a microchip.18
Electrophoresis in microdevices with hydrophilic polymer sieving matrices and coatings is thus
an attractive potential platform for quantifying TK1.
In the present study I report the use of a monoclonal anti-TK1 antibody10 to detect
immune complexes with as low as 80 nM TK1 using microchip electrophoresis. I used FITClabeled anti-TK1 antibodies to monitor the formation of the immune complex. I explored the
effect of commonly used buffers on immune complex formation and found a strong buffer
dependence. I also studied the effect of buffer viscosity on the separation and peak shape. After
identifying an appropriate buffer and sieving matrix I was able to develop an easy to perform
microchip electrophoresis assay of Ab-TK1 complexes. This approach could potentially be
adapted for detecting TK1 in serum for early diagnosis of cancer or its recurrence.

2.2 EXPERIMENTAL SECTON
2.2.1 Materials and Reagents.
Methylcellulose (MC) of different molecular weights (14000, 41000, and 88000 Da) was
purchased from Sigma-Aldrich (St Louis, MO). Tween 20 was acquired from Mallinckrodt
Baker (Paris KY). Sodium chloride came from Columbus Chemical (Columbus, WI). Tris-base
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and 10x phosphate buffer saline were from Fisher Scientific (Fair Lawn, NJ). Boric acid, glycine
and hydrochloric acid were obtained from EMD Chemical (Gibbstown, NJ). Fluorescein
isothiocyanate (FITC) and ethylenediaminetetraacetic acid (EDTA) were purchased from Life
Technologies (Carlsbad, CA). Centrifugal filters were from Millipore (Billerica, MA).
Poly(methyl methacrylate) (PMMA) substrates were purchased from Evonik (Parsippany, NJ).
All solutions were made using deionized water, 18.3 MΩ.
2.2.2 Buffer preparation. 1% MC solutions were prepared as recommended by the
manufacturer. Briefly, MC was first dissolved in deionized water at 80°C, and then the
corresponding buffer volume was added to the solution. Cold deionized water (~4°C) was next
added up to the required volume and the solution was stored at 4°C for 1 hour. The buffer was
then agitated at room temperature for at least 1 hour, resulting in a clear and viscous solution. All
buffer solutions had Tween-20 added to 0.01% and were stored at room temperature after
preparation.
2.2.3 Device Fabrication. PMMA microchips were fabricated using adaptations of protocols
reported previously.19 Silicon templates were made in the BYU Integrated Microfabrication Lab
using standard photolithography techniques to provide elevated channel features (20 µm tall, 50
µm wide) in a T design. Microchannel features were hot embossed onto 1.5 mm thick PMMA
sheets (2 x 5 cm2) for 30 minutes at 138°C. 3-mm thick PMMA sheets (2 x 5 cm2) with laser-cut
reservoirs were thermally bonded as cover plates for 27 minutes at 110°C to enclose the
microfluidic channels.
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2.2.4 Sample Preparation. Mouse anti-human TK1 monoclonal antibodies10 were conjugated
with FITC as described previously.20 Excess FITC was removed using Amicon Ultra-0.5
centrifugal filters (30 kDa). Concentrations of the stock antibody were measured to be 1 mg/mL
using a Nanodrop ND-1000 spectrophotometer (Nanodrop Technologies, Wilmington, DE).
FITC-conjugated antibodies were tested for TK1 binding using dot blots on nitrocellulose
membranes. Labeled antibodies were stored in 1X PBS at 4°C. Human recombinant purified
TK1 was obtained from Genscript (Piscataway, NJ). Full length human TK1 was expressed with
a histidine tag, which was used for purification and then subsequently cleaved.
2.2.5 Contact Angle Measurement. MC (1% w/v) was prepared in 20 mM Tris-HCl buffer.
PMMA sheets (2 x 2 cm2) were washed with deionized water and dried with nitrogen. MC
solutions (1 mL) were then placed on one side of a PMMA sheet and incubated for 30 minutes;
then excess solution was completely removed by blowing using nitrogen flow. A 10 µL drop of
deionized water was placed on the surface, and the static contact angle was immediately
measured using a goniometer (Rame-Hart, Succasunna, NJ). Three contact angle measurements
were used to measure standard deviation and average.
2.2.6 Device Operation. Separations were done with “pinched” injection,20 using +350 V as the
intermediate potential and +850 V as the high voltage. A laser-induced fluorescence system
coupled with an inverted confocal microscope and a photomultiplier tube was used for detection,
as reported previously.21 The data were collected at 20 Hz using software written in LabView.
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2.3 RESULTS AND DISCUSSION
One of the challenges in using PMMA for microfluidics is its hydrophobicity that affects
reproducibility in separation of proteins.22 Cellulose-based polymer dynamic coatings are
effective at inhibiting the nonspecific adsorption of proteins in polymer microfluidic devices by
increasing the hydrophilicity of the surface.23 Three different molecular weight MCs were
evaluated as dynamic coatings. As shown in Table 2.1, treatment of the surface with buffer
containing 1% MC of all molecular weights decreased the PMMA contact angle. PMMA
treatment with the lowest molecular weight MC (14000 Da) increased the hydrophilicity of the
surface the most as indicated by the least contact angle.
Table 2.1 Effect of 1% w/v MC treatment on PMMA surface contact angle.

MC mol wt. (Da)
No MC
14000
41000
88000

Contact Angle
71.5 + 0°
16.6 + 2.5°
30.5 + 0.9°
33.2 + 0.9°

The choice of buffer affects the formation and stability of immune complexes.
Theoretically, the best separation can be achieved by applying high voltage in a buffer having
low conductivity. For example Tris-glycine buffer is commonly used for capillary
electrophoresis because it has low conductivity and current under high voltage.24,

25

I tested

several common electrophoresis buffers for sample flow by positioning the laser at the channel
intersection point and measuring the fluorescence over time when voltage was applied (see Table
2.2). I also observed the current during this process as noted in Table 2.2, with low currents
<30 µA and high currents greater than this value. Although the current was low, no sample flow
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was observed in channels when Tris-glycine buffer was used, even at potentials up to +1450 V.
This could be due to effects of this buffer and/or MC on the mobility. Moreover, I observed that
when 1X PBS was used, the current was high and particles were seen under microscope
observation inside the microchannels, perhaps due to Joule heating that partially evaporated the
solvent, resulting in buffer salt or MC deposits. Both 0.5X PBS and 1X Tris-borate EDTA (TBE,
90 mM) yielded the desirable combination of low current and sample flow when voltage was
applied.
Table 2.2 Current and sample flow for different buffers.

Buffer
1X PBS, pH 7.4
0.5X PBS, pH 7.4
25 mM Tris-192 mM glycine,
pH 8.3
90 mM Tris-borate EDTA, pH 8.0

Sample Flow
Yes
Yes
No

Current
High
Low
Low

Yes

Low

I noted that separation distance affects the protein peak height and shape.
Electropherograms of the anti-TK1 antibody by itself showed that increasing the separation
distance to the detection point resulted in peak broadening and a decrease in peak height.
Background-subtracted peak height increased as separation distance was decreased from 15 to 10
and 5 mm (Figure 2.1A-C; 0.14, 0.16, and 0.21 units). Peak full width at half maximum
(FWHM) also decreased (7.2, 5.5, and 4.7 s) with these same decreasing separation distances.
Previously it has been shown that the choice of buffer can affect immune complex
formation.26 I tested separations in 1X TBE, pH 8.0 with 1% w/v MC-88000. TBE buffer
resulted in sharper peaks, but resolution between the anti-TK1 antibody peak and the immune
complex peak was not observed (see Figure 2.2). The inability to separate or detect the immune
complex under this condition may be due to the instability of the complex at pH 8. As in Figure
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2.1, peak broadening was observed with increased separation distance, with FWHMs of 0.15,
0.20, and 0.25 s for 5, 10 and 15 mm separation distances, respectively. Peak height also
decreased with increased separation distance (2.4, 0.9, and 0.6 units for 5, 10 and 15 mm,
respectively) as was observed in 0.5X PBS (Fig. 2.1). In Figs. 2.1 and 2.2 band broadening with
incraseased separation distance is caused by longitudinal diffusion during the longer separation
times. In subsequent immunoaffinity separations, where Ab and antigen-Ab complexes are
resolved (e.g. Fig. 2.3), additional broadening could occur from greater dissociation of formed
antigen-Ab complexes with longer separation times or distances, although these conditions were
not studied.
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FITC
Ab
A
B
C

Figure 2.1 Effect of separation distance on peak shape. A decrease in peak intensity and increase in
peak broadening were observed as separation distance was increased. Injection was at +350V and
separation was at +850V; separation distances are (A) 15, (B) 10, and (C) 5 mm. Electropherograms were
offset for clarity.

I observed that 0.5X PBS buffer containing 1% MC-14000 or MC-41000 failed to resolve
free anti-TK1 antibody from immune complex (Figure 2.3 A and B), but buffer with 1% MC88000 resulted in separation of the unbound anti-TK1 antibody from the immune complex
(Figure 2.3C). These observations agree with other studies where higher molecular weight MC
resulted in better separation.14, 15, 23 However, with the increased solution viscosity, I had to inject
for 60 seconds in MC 41000 and MC 88000 to obtain adequate fluorescence signal, while 30
second injection was enough for buffer with MC 14000. A separation distance of 5 mm was
sufficient to resolve the free antibody from the immune complex when 0.5X PBS buffer with 1%
MC 88000 was used; moreover, these separations were faster, so I utilized a 5 mm separation
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distance in subsequent experiments. Increasing the MC concentration above 1% made it difficult
to load the solution into the channel and sometimes resulted in delaminated devices because of
backpressure during filling.

A
B
C

Figure 2.2 Attempted separation of Ab-TK1 complex from free Ab in 1X TBE buffer with different
separation distances. A) 5 mm B) 10 mm C) 15 mm. Sample was 25 µg/mL (156 nM) Ab incubated
with 25 µg/mL (1 µM) TK1; injection and separation conditions were the same as in Fig. 2.1;
electropherograms are offset for clarity.

Using the optimized conditions, I performed microchip electrophoresis of anti-TK1
solutions with increasing pTK1 concentration. Figure 2.4A shows the electropherograms of antiTK1 incubated with different pTK1 concentrations; I found that the immune complex peak
increased as pTK1 concentration was increased. A plot of peak area of the immune complex
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correlated with pTK1 concentration (Figure 2.4B). The immune complex peak was observed at
pTK1 concentrations above 2 µg/mL (80 nM); I was not able to observe the complex peak when
the concentration of pTK1 was lower.

Figure 2.3 Separation of Ab-TK1 complex with different 1% w/v MC additives in 0.5X PBS. A)
MC-14000, 30 s injection B) MC-41000, 60 s injection and C) MC-88000, 60 s injection. Samples were
25 µg/mL (156 nM) Ab incubated with 25 µg/mL (1 µM) TK1. injection and separation conditions were
the same as in Fig. 2.1; electropherograms are offset for clarity.

The clinical concentration of TK1 in serum of cancer patients varies depending on the
type of cancer and can be as low as 2 pM or as high as 50 pM, while the TK1 concentration in
healthy individuals is lower than 2 pM,6 so the detection limit has to be improved for this
approach to be used in cancer screening. Several factors that could be explored to lower
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detection limits by improving antigen-antibody binding are ionic strength, temperature, and pH.
Neutral pH is commonly used for immunoaffinity assays, although research suggests that
immobilized monoclonal antibody to antigen binding capacity may improve as pH decreases to
~3.27 However, not all immune complexes are stable at low pH; further work would be required
to investigate this possibility more fully, which is beyond the scope of this paper. I note that
fluorescence quenching occurs at low pH with FITC, but other dyes with high quantum yield in
low pH solutions could be used.28 Another important factor to consider when analyzing serum
sample is sample processing. Serum is replete with high abundance proteins such as
immunoglobulins and human serum albumin that may interfere with antigen-antibody binding.
Depletion of these high abundance proteins using a commercial serum depletion kit could be
employed prior to microchip electrophoresis. This depletion step could also be incorporated in
the design of microchip device to develop a completely automated analysis of serum.
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Figure 2.4 Microchip immunoaffinity electrophoresis of pTK1. (A) Increasing pTK1 concentration
resulted in increasing immune complex peak size, going from 2-25 µg/mL (0.080-1 µM) pTK1. Injection
and separation conditiones are the same as in Figure 2.3 (B) Plot of Ab-pTK1 peak area as a function of
pTK1 concentration. Best line fit is y = 0.123x + 0.26, R2 = 0.94, sm = 0.014, sb = 0.15 (C) Peak area ratio
of complex and free Ab (which accounts for injection differences) y = 1.085x-1.30, R2 = 0.988 sm = 0.053
sb = 0.60.
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2.4 CONCLUSIONS
I developed a microchip electrophoresis immunoaffinity assay for measuring thymidine
kinase-1 using a monoclonal antibody. I have shown that buffer composition and additives affect
sample flow, formation of immune complexes, and separation of unbound antibodies from
immune complexes. The separation of Ab and Ab-TK1 complex was achieved in 0.5X PBS with
1% methylcellulose (88000 Da). Using optimized conditions I was able to separate the immune
complex from free antibody within a 5-mm separation length.
I am currently working on using the optimized conditions to detect TK1 in clinical serum
samples. Since I monitor the formation of antibody-antigen complex I may be able to detect the
form of TK1, (i.e., dimeric vs tetrameric), based on the electrophoretic mobility of the immune
complex. If I can identify TK1 forms in a simple and rapid test, it would be an attractive
alternative to RIA.
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CHAPTER 3: COMPARISON OF DIFFERENT PROTEIN DEPLETION METHODS TO
IMPROVE THYMIDINE KINASE 1 DETECTION

3.1

INTRODUCTION
Serum contains biomarkers important for diagnostic purposes. However, it is also replete

with abundant proteins such as albumin and immunoglobulin that can hinder the detection of low
abundance biomarkers. Removal of high abundance proteins before sample analysis is often
required to improve detection of low concentrations of biomarkers.1 Thymidine kinase 1 (TK1)
is an enzyme important for the DNA salvage pathway and is elevated in serum of cancer
patients. The concentration of thymidine kinase 1 in serum of cancer patients has been reported
to have a range of 2 pM to 50 pM, whereas non-cancer patients have no detectable TK1
concentration above 2 pM.2 Conventional methods such as precipitation and affinity
chromatography are commonly used sample processing steps to obtain quasi-pure sample with
enriched low abundance proteins.
Precipitation either by salt or solvent takes advantage of the solubility of proteins at
different ionic strengths.3 Choosing the appropriate precipitating agent is important, especially if
the activity or preservation of the protein’s native form is important after processing. Ammonium
sulfate precipitation has been commonly used to precipitate out proteins from complex samples
and yet maintain the proteins’ native form and activity.4 Affinity columns can be specific by
using antibodies or ligands, such as protein A, protein G or cibacron blue. Proteins A and G have
been used to specifically bind Fc regions of immunoglobulins while cibacron dye was used to
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bind human serum albumin.5, 6 Immunoglobulin and albumin make up 60-80% of serum protein
concentration,7 hence removal of these abundant proteins can increase detection sensitivity of
TK1 in serum.
Integration of necessary sample processing steps such as pre-concentration of target
analyte is necessary to develop an automated analysis of complex biological fluids in
microfluidic platforms. Therefore, identification of sample processing steps is necessary to
effectively design automated microfluidic devices. In this chapter, I compared three different
protein depletion methods; ammonium sulfate precipitation, albumin depletion and combined
albumin and immunoglobulin depletion to concentrate purified recombinant thymidine kinase 1
(pTK1) from pTK1-spiked serum. The best method to concentrate pTK1 from serum was
determined to be ammonium sulfate precipitation. Further, I applied ammonium sulfate
precipitation to concentrate endogenous TK1 from cancer and normal serum. The precipitate was
also tested using ELISA to quantify TK1 and kinase assay to determine the difference in activity
of TK1 between cancer and normal serum. ELISA and kinase assay indicated that the
concentration and activity of TK1 was higher in cancer than in normal serum.

3.2

MATERIALS AND METHODS

3.2.1 Serum Preparation. 300 µL of serum from a normal donor obtained after informed
consent under an institutional review board approved protocol was used to prepare the stock
serum sample. 10 µL of pTK1 (1 mg/mL) was added to 300 µL of serum before adding 150 µL
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of 25 mM Tris, 75 mM NaCl, pH 7.5 into the solution. The sample was quickly vortexed, and
150 µL of the spiked sample solution was used for each process described below.
3.2.2 Ammonium Sulfate Precipitation. Ammonium sulfate purchased from Sigma (St. Louis,
MO) was used to make an 80% w/v saturated ammonium sulfate solution. After 1 hour in a
shaker (SCILOGEX, Rocky Hill, CT), the solution was centrifuged at 14 000 rpm for 5 minutes.
The supernatant was transferred into a clean microcentrifuge tube. The volume of saturated
ammonium sulfate used was equal to half of the volume of serum being processed. The solution
was incubated for 30 minutes with mild shaking at 4°C and then centrifuged to separate the
precipitate from the supernatant. The supernatant and the precipitate samples were desalted using
a spin filter with 3 kDa MW cut-off. The precipitate was reconstituted in 150 µL of 25 mM Tris,
75 mM NaCl, pH 7.5.
3.2.3 Albumin Depletion. A Pierce Albumin Depletion Kit was purchased from Thermo
Scientific (Rockford, IL). This kit contained agarose resin with cibacron blue as the affinity
ligand. Briefly, columns were equilibrated with 200 µL of provided wash/binding buffer twice.
150 µL of the prepared serum was incubated in the column for 10 minutes before centrifuging at
12 000 rpm for 1 minute. The depleted serum was again incubated in the column for 5 minutes
before centrifuging the column. The twice-depleted sample was kept at -20°C until use.
3.2.4 Albumin and IgG Depletion. A ProteoPrep Immunoaffinity Albumin and IgG Depletion
Kit was purchased from Sigma-Aldrich (St. Louis, MO). The manufacturer’s protocol for using
the kit was followed. Briefly, columns were equilibrated with 200 µL of 25 mM Tris, 75 mM
NaCl, pH 7.5 twice. 300 µL of serum spiked with 10 µL of pTK1 (1 mg/mL) was prepared. 155
µL of 25 mM Tris, 75 mM NaCl, pH 7.5 was then added into the spiked serum. 150 µL of the
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prepared serum was loaded on a column. The flow-through was again incubated with the same
column, so it was protein depleted twice.
3.2.5 Dot Blot. After protein depletion, the presence of TK1 was assessed qualitatively using
direct dot blot of 3 µL on a nitrocellulose membrane purchased from Bio-Rad (Hercules, CA).
After the samples had dried, the membrane was blocked for 1 hour with 5% w/v non-fat dry milk
(NFDM) dissolved in PBS (Hyclone, Logan, UT). The membrane was probed with a 1:1000
dilution of monoclonal anti-human TK1 or 1:1000 monoclonal rabbit-anti TK1 in 5% NFDM
solution for 1 hour with gentle shaking at room temperature. After washing with PBS three
times, the membrane was probed with a secondary antibody labeled with IRDye 680RD from LICOR (Lincoln, NE) for 1 hour. The membrane was washed with PBS and imaged with a LI-COR
Odyssey near-IR fluorescence scanner (Lincoln, NE).
3.2.6 ELISA. To quantitatively compare the amount of TK1 obtained after processing, 50 µg of
serum was incubated overnight in 96-well plates purchased from Corning (Tewksbury, MA).
Nonspecific binding was minimized by blocking the well surfaces with 300 µL of 20 µg/mL
BSA dissolved in Pierce Protein-Free T 20 PBS (Rockford, IL) for one hour at room temperature
with gentle shaking. Each well was washed 4 times with 400 µL of PBS buffer after incubation.
50 µL of 1 µg/mL primary antibody conjugated to horseradish peroxidase (HRP) diluted in 20
µg/mL BSA solution was used to probe for the presence of TK1. For rabbit anti-TK1 antibody,
indirect ELISA was performed using a goat-anti rabbit secondary antibody conjugated to HRP
from

Millipore

(Temecula,

CA).

Before

addition

of

HRP

substrate,

3,3′,5,5′-

tetramethylbenzidine (TMB) from Thermo Scientific (Rockford, IL), each well was washed 4
times with 300 µL of PBS buffer. The reaction was allowed to proceed for 30 minutes and the
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reaction was stopped using 50 µL of 2 M H2SO4. Absorbance was measured at 450 nm using a
Biotek Synergy H4 Hybrid Microplate Reader (Winooski, VT).
3.2.7 Denaturing Polyacrylamide Gel Electrophoresis (PAGE). NuPAGE 10% BisTris Gel
from Novex (Carlsbad, CA) was used for SDS PAGE. Samples were separated using 1X SDS
MOPS buffer at 120 V and 4°C for about 1 hour.
3.2.8 Native PAGE. 6% Tris boric acid gel, pH 8.7 was prepared with 6% Tris-HCl stacking
gel, pH 8.0. Samples were separated using 1X Tris boric acid buffer, pH 8.7 at 200 V and 4°C
for 2 hours.
3.2.9 Western Blot. A nitrocellulose membrane was used for western blots. Protein transfer was
performed for 1 hour at 100 V using 25 mM Tris, 250 mM glycine buffer with 20% v/v
methanol. The membrane was blocked with 5% w/v NFDM in PBS for 1 hour and then
incubated with a 1:1000 dilution in 5% w/v NFDM in PBS of rabbit anti-TK1 purchased from
Epitomics (Burlingame, CA) and mouse anti-TK1 overnight at 4°C. The membrane was then
washed three times with PBS. The two secondary antibodies purchased from LI-COR were IR
Dye 800CW labeled donkey anti-rabbit and goat anti-mouse. After 1 hour of secondary antibody
incubation at room temperature, the membranes were washed with PBS and imaged using a LICOR Odyssey (Lincoln, NE) near-IR fluorescence scanner.
3.2.10 Kinase Assay. A universal kinase kit assay from R&D Systems (Minneapolis, MN) was
used to analyze kinase activity in 15 µg of protein per sample. The instructions as recommended
by the manufacturer were followed. Briefly, samples were loaded into a 96-well plate and the
reagents were added as directed. After the reaction, the sample absorbance was measured at 620
nm using a Biotek Synergy H4 Hybrid Microplate Reader.
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3.3

RESULTS AND DISCUSSION
Protein content of processed serum samples was measured using a ND-1000

spectrophotometer (Nanodrop Technologies, Wilmington, DE) and compared with unprocessed
serum as reported in table 3.1. Protein content decreased the most using ProteoPrep
Immunoaffinity Albumin and IgG Depletion Kit which resulted in retention of 24.6% of protein
in the flow-through while Pierce Albumin Depletion Kit and precipitate from ammonium sulfate
contained 51.5% and 46.3% of protein, respectively, compared to unprocessed pTK1 spiked
serum. A dot blot was performed to qualitatively assess if the pTK1 was retained after
processing, and results shown in Figure 3.1 indicated that both albumin depletion and
immunoaffinity depletion kits confirmed presence of pTK1 in the flow-through after serum
processing. Also, precipitate from ammonium sulfate processing indicated more concentrated
pTK1 as indicated by the darker spot compared to the supernatant.
.

Table 3.1 Protein concentration after protein depletion. Average of 3 measurements of total protein
after processing of pTK1-spiked serum
Sample Processing
ammonium sulfate precipitation
(precipitate)
ProteoPrep Immunoaffinity
Albumin and IgG Depletion Kit
Pierce Albumin Depletion Kit
Unprocessed serum

Average Protein
Concentration (mg/mL)
31.0

% Protein after
processing
46.3

16.5

24.6

34.5
67.0

51.5
100

Since it was difficult to quantitatively analyze the results of dot blots, ELISA was utilized
to measure the presence of pTK1 in each processed serum sample, based on the absorbance at
450 nm. ELISA results in Figure 3.2 indicated that ammonium sulfate precipitation had the
highest concentration of pTK1 per 50 µg of total protein while albumin depletion resulted in the
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least concentration of pTK1. The Pierce Albumin Depletion Kit used cibacron dye to bind
human serum albumin. It has been reported that cibacron dye binds non-specifically,8 which may
explain the low concentration of pTK1 in the processed serum. On the other hand, ProteoPrep
Immunoaffinity Albumin and IgG Depletion Kit uses antibody ligands, which specifically bind
to human albumin and IgG.

Figure 3.1 Dot blot analysis for presence of pTK1 after processing of spiked serum samples. Mouse
monoclonal anti-TK1 was used to probe for presence of TK1. 3 µL of each sample was blotted twice on a
nitrocellulose membrane. Dark spots indicate presence of pTK1 in the sample. 1,2) Precipitate after
ammonium sulfate precipitation. 3,4) Supernatant after ammonium sulfate precipitation. 5,6) Flowthrough after processing with ProteoPrep Immunoaffinity Albumin and IgG Depletion Kit. 7,8) Flowthrough after processing with Pierce Albumin Depletion Kit.

Because ammonium sulfate precipitation contained the most pTK1, cancer serum was
also processed using this method. Figure 3.3 shows the ELISA results that indicate successful
concentration of endogenous TK1 in the precipitate. The average (n=3) calculated amount of
TK1 per 50 µg of total protein in cancer serum precipitate was 8.5 + 0.02 ng compared to
6.1 + 0.1 ng in normal serum precipitate. For 5 µg of total protein, TK1 concentrations were
5.8 + 0.02 ng and 4.8 + 0.03 ng for cancer and normal serum, respectively. The decrease in total
protein (from 50 µg to 5 µg) is expected to result in lower TK1 concentration, as observed. This
was done to determine if the signal obtained in the ELISA was dependent on the concentration of
TK1.
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Figure 3.2 Comparison of ELISA results after protein depletion of pTK1-spiked serum. Ammonium
sulfate treatment precipitate retained the most pTK1 followed by ProteoPrep Immunoaffinity Albumin
and IgG Depletion Kit, while Pierce Albumin Depletion Kit retained the least pTK1 after protein
depletion. 50 µg of total protein was used for each sample analysis. The error bars represent the standard
error of the mean (SEM) (n=3).

Figure 3.3 ELISA of ammonium sulfate precipitation of cancer serum and normal serum.
Endogenous TK1 was effectively concentrated in the precipitate. An increase in signal was observed in
the precipitate compared to the unprocessed serum. Error bars represent the SEM (n=3).
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To verify that that the ELISA results correspond to TK1 in serum and not non-specific
binding, western blots were performed. Western blots of denatured proteins were probed together
with the novel mouse anti-TK1 and commercial rabbit anti-TK1 (Figure 3.4). Rabbit antibody
(see Figure 3.4A) bound to proteins in all lanes, including normal serum precipitate and cancer
serum precipitate. Multiple protein bands were present in pTK1, pTK1-spiked, and cancer serum
precipitate, while only one band (>50 kD, corresponds to dimer form) was present in normal
serum precipitate (Figure 3.4A, lane 1). Cancer serum was postive for ~120 kD band that
corresponds to the tetrameric form of TK, which has higher kinase activity than the dimer form
(Figure 3.4A, lane 3). As expected, pTK1-spiked normal serum precipitate (Figure 3.4A-C, lane
5) showed the most binding when probed with both antibodies. These results indicate that serum
processing is important to detect other possible TK1 isoforms. On the other hand, the novel
mouse anti-TK1 bound less protein and also exhibited more nonspecific binding as shown by the
presence of random red fluorescence on the membrane (Figure 3.4C). It also only showed strong
binding in pTK1 and ammonium sulfate processed pTK1-spiked protein (lanes 5 and 6,
respectively, Figure 3.4B).
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Figure 3.4 Western blot analysis of processed serum samples after SDS PAGE. 1) Normal serum
precipitate, 2) IgG and albumin depleted spiked normal serum, 3) precipitate from cancer serum, 4)
albumin depleted spiked normal serum, 5) precipitate from pTK1-spiked normal serum, 6) pTK1 sample
and 7) protein ladder. Blots were probed with A) monoclonal rabbit anti-TK1 and B) monoclonal mouse
anti-TK1; intensity was adjusted to emphasize the faint bands. C) Merged image; yellow indicates both
antibodies bind to the protein. 50 µg of total protein was loaded for each serum sample, while 2 µg of
pTK1 was used as positive control.

I performed western blot analysis of native PAGE to determine if the mouse anti-TK1
could only recognize endogenous TK1 in its native form because of the absence of binding to
endogenous TK1 in the denatured western blots. Figure 3.5A shows binding of rabbit antibody to
pTK1 (lane 1) and endogenous TK1 from serum cancer. In contrast, mouse anti-TK1 still bound
only to pTK1 (Figure 3.5B, lane 1) but did not bind to endogenous TK1 in processed cancer
serum (lane 2). The difference in migration distance suggests that pTK1 has different physical
characteristics than the endogenous TK1.
The observed difference between binding patterns in denatured and native TK1 could
also suggest that the antibodies have different binding affinities. To answer that question, ELISA
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was performed to determine the dissociation constant, Kd, of the two antibodies. The antigen
used to calculate the dissociation constant was pTK1. Using the equation y = x*Bmax/(x+Kd)
the calculated Kd’s were 4.88 + 0.98 nM and 1.38 + 0.16 nM for mouse and rabbit antibodies,
respectively (Figure 3.6). The Kd values suggest that the rabbit antibody is more sensitive than
the mouse antibody. However, the calculated Kd values were only about a factor of 3 different,
which should not result in dramatic differences in the binding pattern. Therefore, the non-binding
of mouse anti-TK1 to endogenous TK1 and the presence of non-specific binding as observed in
both native (Figure 3.4) and denatured (Figure 3.5) western blots suggest that the ELISA could
be a false positive. Another factor that could result in no binding in the western blot would be the
change in structure of TK1 in any of the stages of the western blot, such as the protein transfer
step where 20% methanol was included in the buffer, resulting in loss of the epitope
conformation identified by mouse anti-TK1.
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Figure 3.5 Native PAGE of pTK1 and endogenous TK1. 1) pTK1. 2) Precipitate from cancer serum.
Blot probed with A) rabbit anti-TK1 and B) mouse anti-TK1 antibody. C) Merged image of A and B;
yellow color in lane 1 indicates binding of both mouse and rabbit antibodies.

Finally, to ensure that the rabbit antibody was indeed binding pTK1, kinase activity was
tested in the precipitate of cancer and normal serum and unprocessed counterparts. Kinase
activity was detected in cancer serum samples before and after ammonium sulfate precipitation,
but activity was detected above the noise level in normal serum only after ammonium sulfate
precipitation (Figure 3.7). From the obtained absorbance values, TK1 activity was calculated
based on the amount of adenosine diphosphate produced as described by the manufacturer. The
calculated TK1 activity in unprocessed serum was 1.6 pmol/min/µg of total protein but increased
to 19.2 pmol/min/µg of total protein in the ammonium sulfate precipitate. In normal serum,
kinase activity was undetected in unprocessed serum, increasing to 1.5 pmol/min/µg of total
protein in the ammonium sulfate precipitate. The increase in activity indicated that TK1 was
concentrated after processing. I can also infer from this result that the positive binding of rabbit
antibody in western blot results for the cancer serum precipitate was due to the presence of TK1.
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Figure 3.6 Kd curve fitting. Equation used was x*Bmax/(x+Kd). Antigen used was pTK1.

After having established that rabbit anti-TK1 binds TK1 in western blots, endogenous
TK1 from cancer and normal serum samples was measured using indirect ELISA with the rabbit
antibody. Figure 3.8 shows that TK1 concentration was higher in cancer than in normal serum,
and the difference was more pronounced at 50 µg of total protein (0.98 + 0.01 ng in cancer and
0.61 + 0.01 ng normal serum) than in 5 µg of total protein (0.59 + 0.00 ng in cancer and 0.44 +
0.00 ng in normal). The same trend as in direct ELISA was observed with mouse anti-TK1
though the measured concentrations of TK1 were different from each other. The similar trend of
concentrations suggest that the earlier assumption that the presence of methanol in the transfer
buffer may have affected the TK1 conformation resulting in negative binding of mouse anti TK1.
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If this is the case, then mouse anti-TK1 is quite sensitive to conformational changes of
endogenous TK1, and it may be difficult to use on different platforms. Therefore, it is important
to determine what conformation of endogenous TK1 the mouse anti-TK1 binds, perhaps by
immunoprecipitation and mass spectrometry analysis.

Figure 3.7 Comparison of kinase activity. Kinase activity before and after ammonium sulfate
precipitation of cancer and normal serum samples. Error bars represent SEM (n=3).
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Figure 3.8 Indirect ELISA of ammonium sulfate precipitate from cancer and normal serum using rabbit
anti-TK1. Error bars represent SEM (n=3).

3.4 CONCLUSIONS
Choosing the appropriate commercial kit for protein depletion must be carefully studied
to determine if the target analyte will be lost or retained during the process. I have demonstrated
that ammonium sulfate precipitation retained the most pTK1 followed by Proteo Prep
Immunoaffinity Albumin and IgG Depletion Kit, while Pierce Albumin Depletion Kit retained
the least pTK1 among the three processes. Ammonium sulfate precipitation was also effective at
concentrating endogenous TK1 from serum while maintaining its activity.
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ELISA, western blot and kinase assay results showed that processing was important to
clearly differentiate cancer from normal serum. Though the samples tested here were limited,
these results give direction on how to process serum samples for future work. I also determined
that rabbit anti-TK1 binds to both pTK1 and endogenous TK1 while the mouse anti-TK1 binds
only to pTK1 in the conditions used in these experiments. The difference in migration time in
native PAGE of endogenous TK1 from pTK1 indicates that the two proteins have different
physical properties. This result agrees with the early studies of recombinant TK1 reported by
Munch-Petersen et al.9 where they attributed the differences in TK1 physical properties to
different post-translational modifications that may take place depending on the type of cell used
in cloning the recombinant protein. Furthermore, the presence of higher molecular weight bands
in cancer serum in denaturing PAGE hints that the different isoforms of TK1 are worth further
investigation.
Processed serum samples showed about 13 fold more activity in cancer than in normal
serum. It is interesting to note that the concentration of TK1 in cancer serum was only about 1.4
fold higher than normal. These findings solidify the previous reports that the difference in
activity of TK1 is dependent on its isoform, where higher molecular weight TK1 have higher
activity than low molecular weight TK1. Recent findings by Jagarlamudi et al10 also indicated
that at early stage of cancer, particularly prostate and breast, had higher fractions of less active
dimer form of TK1. Therefore, for future studies, serum processing and profiling of the different
isoforms of TK1 at different stages could be helpful in developing a TK1 assay for early
detection of cancer.
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CHAPTER 4: OPTIMIZATION OF MONOLITHIC COLUMNS FOR MICROFLUIDIC
DEVICES ∗

4.1 INTRODUCTION
Disease-specific biomarkers are important for proper diagnoses and treatments of
diseases. For example, a panel of biomarkers such as proteins, metabolites, or nucleic acids can
be probed to diagnose or monitor treatments of some diseases. Proteins and metabolite
biomarkers are heavily studied because they are relatively easy to obtain in different biological
fluids. Protein biomarkers are generally detected contingent on the availability of the
corresponding antibody. Extracellular nucleic acid biomarkers of diseases have also been found
in urine,1, 2 serum3, milk,4 cerebrospinal fluid,5 and saliva6. However, detection of nucleic acid in
biological fluids is hindered by low concentration. Additionally, short nucleic acid fragments
such as miRNA are difficult to detect because they are almost the same size as primers used in
PCR. Therefore it should be beneficial to develop sensitive and easy assays that can analyze
these panels of biomarkers for point-of-care diagnostics.
Analysis of panels of biomarkers is desirable for point-of-care diagnostics, potentially
enabling routine tests to be performed easily and inexpensively. Assessment of tumors for
example, currently requires aseptic techniques and expensive personnel time to obtain a tissue
sample to confirm disease.7 Also, tissue sample size is limited to reduce discomfort to the

∗
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patient. Blood contains important biomarkers. Although less invasive compared to biopsy, sterile
needles and aseptic techniques are still required. On the other hand, biological fluids such as
urine and saliva can be obtained non-invasively and multiple times to obtain sample in a day if
needed. An assay that can analyze small volumes of biological fluids, produce rapid results, and
be easy to use is necessary for point-of-care diagnostics.
Some methods of detecting biomarkers are immunoassays,8 PCR,9 and mass
spectrometry.10,

11

These methods are sensitive and high throughput but are expensive and

tedious, requiring multistep sample preparations and specialized machines. Immunoassays are
also dependent on the availability of antibodies for the target antigens. PCR for detecting nucleic
acids requires expensive reagents and sample purification. Mass spectrometry instruments are
expensive and incompatible with samples containing particulates, high salt, and surfactants, thus
requiring sample pre-treatments. Therefore, there is a need for fast, simple, and cheap assays for
point-of-care applications.
Microfluidic devices are useful in handling nanoliter to picoliter biological fluid samples,
with strong potential to decrease analysis time. Some applications of microfluidic systems are for
genomic sequencing,12 protein analysis,13 cell sorting,14 and PCR.15 Because microfluidics are
effective in analyzing small volumes, reagent usage is also dramatically reduced. Such devices
are generally small, enabling portability, while microfabrication technology facilitates mass
production. The desire for automated sample analyses has led to integration of different sample
treatment methods on the devices such as on-column labeling,16 pre-concentration,17, 18 and target
extraction using solid phase extractors.19 These integrated functions in microfluidics devices are
promising applications in point-of-care diagnostics.
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Here I describe the integration of functionalizable monoliths as affinity columns in
microfluidic devices. Typical monolithic columns in chromatography separations require
pressure20, 21 to flow the samples through. Applied voltages offer a simplified way to flow the
sample through the monolithic columns. However, bubble entrapment in monoliths is a frequent
problem when electric fields are applied across monolithic columns. Therefore it is necessary to
make monolithic columns that are porous enough that air bubbles are not trapped during
capillary flow. Here I show an optimized process for making glycidyl metharcylate-ethylene
glycol dimethacrylate monolithic columns. I used cyclohexanol and 1-dodecanol as porogens,
with the surfactant Tween 20, which increased the pore size. The amount of porogens affected
the nodule morphology and size of pores. The monoliths formed are very porous as water and
buffer can flow through the monoliths by capillary action.

4.2 MATERIALS AND METHODS
4.2.1 Materials and Reagents. Polyethylene glycol dimethacrylate (PEGDMA), ethylene glycol
dimethacrylate (EGDMA, 98%), glycidyl methacrylate (GMA, 97%), 2,2-dimethoxy-2phenylacetophenone (DMPA, 98%), and 1-dodecanol (98%), were from Aldrich (Milwaukee,
WI). Cyclohexanol was from J. T. Baker (Phillipsburg, NJ). Tween 20 was from Mallinckrodt
Baker (Paris, KY).
4.2.2 Monolith preparation in glass vials. Porogens, monomers, and photoinitiator were
weighed according to the amounts indicated in Table 4.1, mixed together and ultrasonicated until
the photoinitiator was completely dissolved. The total weight of the mixture was 1 g. 0.5 g of
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the mixture was transferred into another clear clean glass vial and 0.2 g of Tween 20 was added
into the mixture. The solutions with and without Tween 20 were sonicated again for five minutes
before photopolymerization in the glass vials under UV exposure using a Sunray 400 lamp
(Intelligent Dispensing Systems, Encino, CA) for 12-15 minutes at 200 W. Higher porogen
levels resulted in increased in polymerization time. After polymerization, monoliths were cooled
to room temperature. Immediately after cooling, the monoliths were placed in separate thimbles
and cleaned using Soxhlet extraction apparatus overnight using 2-propanol as solvent. The
monolith was then gently washed with deionized water several times and air dried before
scanning electron microscope imaging.
Table 4.1 Monolith composition

Monomer Crosslinker
(g)
(g)

Porogens (g)

Monolith

GMA

EGDMA

cyclohexanol

A
B
C
D
E
F

0.25
0.25
0.20
0.20
0.2
0.2

0.25
0.25
0.20
0.20
0.1
0.1

0.25
0.25
0.30
0.30
0.30
0.30

1dodecanol
0.25
0.25
0.30
0.30
0.40
0.40

Surfactant
Photoinitiator
(g) per
(mg)
0.5g of
mixture
DMPA
Tween 20
20
20
20
20
20
20

0
0.2
0
0.2
0
0.2

4.2.3 Microfabrication of microfluidic devices. The fabrication process for making
microfluidic devices has been previously described.22,23 Briefly, photolithography was used to
transfer the channel design on oxidized silicon which had been spin coated with SPR 1805
photoresist (MicroChem Corp., Newton, MA). After development, the silicon was etched with
HF until the silicon wafer became hydrophobic, followed by a KOH etch to achieve a channel
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depth of about 20 µm. The microfluidic design was transferred onto PMMA by hot embossing.
PMMA with laser cut holes was then thermally bonded to enclose the channels.
4.2.4 In-situ polymerization of monoliths in microfluidic channels. The initial procedure for
preparing the solutions was similar to that described for monolith preparation in glass vials
except the solution was purged with nitrogen gas after ultrasonication. Then, the solution was
flowed by capillary action into the microfluidic channel. Excess solution in the reservoir was
removed to limit hydrodynamic flow during polymerization. Black tape was used to mask other
parts of the channel to contain polymerization of the solution in target area only. The device was
then exposed to UV light using a PRX 1000 (Tamarack Scientific, Corona, CA) lamp with power
of 1 kW for about 12 minutes. The monoliths were immediately washed with 2-propanol until
the monolith became white in color, then washed with deionized water several times and dried at
room temperature.
4.2.5 Scanning electron microscopy imaging. The channel containing the monolith was laser
cut and glued on plastic stubs. The edge that contained the end of the channel with monolith was
cut using a manual microtome with a glass knife until the monolith was exposed. The surface
was cleaned using scotch tape to remove debris. Samples were mounted on aluminum stubs
using carbon tape and coated with gold using a Polaron Gold Sputtter for 3 minutes to decrease
charging. The samples were coated under 0.1 Torr, with an applied potential of 2.5 kV and
current maintained at 18-20 mA. The gold coating under these conditions was about 20 nm. All
images were taken using a Philips XL30 ESEM FEG in low vacuum mode using a gaseous
secondary electron detector. Voltage applied varied from 10-12 kV since the monoliths charged
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differently. However, the magnifications and working distances were similar for each set to
make comparison easier.
4.3. RESULTS
4.3.1 PEGDMA vs. EGDMA Crosslinkers. Figure 4.1 compares SEM data for GMAPEGDMA and GMA-EGDMA monoliths. The GMA-PEGDMA monolith has smaller nodules
than the GMA-EGDMA monolith. Smaller nodules mean more surface area for immobilizing
probes. The smaller nodule of GMA-PEGDMA is due to the poorer cross-linking efficiency of
PEGDMA.24 Also with GMA-PEGDMA, the SEM image shows smaller pores; hence, more
pressure would be needed to flow the liquid through the monolith. Water did not flow through
in-situ polymerized GMA-PEGDMA, while partial flow was observed in GMA-EGDMA
monoliths. Thus, no other formulation was tried using PEGDMA crosslinker. Instead, I decided
to optimize GMA-EGDMA monolith formulation targeting irregular large through pores, high
surface area, mechanical stability, and surface amenable for functionalization. High surface area
increases diffusion mass transport and irregular pores enhance convective transport as liquid
flows through the monolith.25

78

A

B

Figure 4.1 SEM images of (A) GMA-PEGDMA and (B) GMA-EDGDMA monoliths show different
globule formations. Both monoliths were made by mixing 0.3 g cyclohexanol, 0.4 g 1-dodecanol, 10 mg
DMPA, 0.1 g GMA, and 0.25 g EGDMA or PEGDMA.

4.3.2 Comparison of morphology of GMA-EGDMA monoliths. One way of controlling the
pore size is by changing the porogen concentration. I observed that a total porogen of mass 0.80
g resulted in a soft monolith when exposed for 12-15 minutes. Therefore, I selected a maximum
total porogen of 0.7 g. Monolith solution with surfactant content more than 0.2 g produced
bubbles after ultrasonication and during nitrogen purging; these bubbles hindered flow of
solution through the microchannels. Thus, surfactant content ≤0.20 g was used.
SEM images in Figure 4.2 show the effects on the morphology of the nodules and pore
size by varying two parameters: porogen content (A, C and E) and presence or absence of Tween
20 surfactant (B, D, and F). Increasing only the total porogen resulted in larger nodule size but
at 70% (wt/wt) the globular nodules became somewhat fused. The monoliths without Tween 20
(A, C and E) have through pores that range from ~1 µm (A) to ~2.5 µm (C). However, in the
solution with 60% porogen (C), only increased size of the globular nodules was observed.
Mechanically weak monoliths were produced when total porogen was greater than 70% (wt/wt)
under the same polymerization conditions. Addition of surfactant also increased pore size.
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Adding 0.2 g of Tween 20 increased the pore size from ~2.5 µm (E) to ~ 4 µm (F). It has been
suggested that surfactants in emulsions affect phase separation during polymerization.26 I tested
the following surfactants: sodium dodecyl sulfate, polystyrene sulfonate sodium salt, and Tween
20. Tween 20 gave the best result in terms of homogeneity of solution.
A

C

BB

C

D

E

F
D

Figure 4.2 SEM images of GMA-EGDMA monoliths under different compositions. A, C, and E are
GMA-EGDMA monoliths while B, D, and F are the corresponding monoliths with 0.2 g of Tween 20 as
well. See Table 4.1 for detailed information for each monolith. Increasing the total porogen concentration
results in an increase in size of the nodules (A, C, E). Addition of Tween 20 increases the size of throughpores.

80

4.3.3 Optimal monolith formation in microdevices.

Because of the large pore size, the

monolith with 70% porogen (F) was in-situ polymerized in a microchip (Figure 4.3), and
capillary flow was observed. In an in-situ polymerized monolith without the surfactant (E), air
bubbles formed in the monolith when water flowed through were difficult to remove. In contrast,
the addition of surfactant to 70% porogen monolith resulted in less bubble trapping and water
flowed through the monolith by capillary action.
This optimized formulation is advantageous for integrating monolithic columns in
microfluidic devices. The monoliths formed, though porous, exhibit high surface area with
functionalizable surface. Also, because the liquid solutions can flow through the optimized
monolith by capillary action, surface modification of the monolith will be easier, and
electrophoretic flow can be used to move fluid through the monolith instead of pumps.

Figure 4.3 SEM image of in-situ polymerized monolithic column in a microfluidic device.
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4.4 CONCLUSION
I have optimized in-situ polymerized GMA-EGDMA monolithic columns in microfluidic
devices. Nodule size and through-pore dimensions increased with increasing porogen content
and addition of the surfactant, Tween 20. Capillary action was sufficient to flow water through a
monolith with a composition of 70% porogen and added surfactant. The presence of epoxy
groups on the surface can be utilized for immobilizing single-stranded DNA probes for on-line
extraction of single stranded nucleic acid biomarkers in biological fluids.
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CHAPTER 5: MONOLITH AFFINITY EXTRACTION OF INTERLEUKIN-8, A
POTENTIAL CANCER MARKER, FROM SALIVA IN MICROFLUIDIC DEVICES

5.1 INTRODUCTION
Oral squamous cell carcinoma (OSCC) of the head and neck is one of the most common
cancers worldwide characterized by high morbidity and mortality rate.1 The survival rate is about
50%, 5 years after detection, because it is often diagnosed at the late stage of the disease.2 The
known risk factors of oral cancer are tobacco use and alcohol consumption. Human papilloma
virus has also been linked to oral and oropharyngeal cancer.3,

4

The standard for diagnosing

OSCC is through biopsy and immunohistochemistry testing of lesions found in mucosal
surfaces.2 However, the unrealiability of histologic grading spurs increased interest in identifying
molecular markers that will be useful for accurate and early stage diagnosis.5
Interleukin 8 (IL8) is a chemokine implicated in the tumorigenesis and metastasis in
OSCC.6 It has been reported that IL8 in saliva was detected at higher concentrations in cancer,
86 pM, than in normal patients, 30 pM.5, 7, 8 A saliva-based test could be a cost-effective and
non-invasive early diagnosis or follow-up in conjunction with conventional diagnostic methods.
In this chapter, I describe a process of integrating monolith affinity columns in
poly(methyl methacrylate) (PMMA) devices. I also test the ability of these affinity columns to
extract IL8 in buffer and in spiked saliva. Preliminary results show successful immobilization of
active antibody and extraction of IL8 from buffer and saliva. However, decreased extraction
efficiency of IL8 from saliva compared to IL8 in buffer is observed. These results are
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encouraging to pursue further development of microchip immunoaffinity assays for detecting
potential disease markers in saliva.

5.2 MATERIALS AND METHODS
5.2.1 Reagents. Ethylene glycol dimethacrylate (EGDMA, 98%), glycidyl methacrylate (GMA,
97%), 2,2-dimethoxy-2-phenylacetophenone (DMPA, 98%), and 1-dodecanol (98%), were
obtained from Aldrich (Milwaukee, WI). Cyclohexanol was from J. T. Baker (Phillipsburg, NJ).
Tween 20, sulfuric acid and acetic acid were purchased from Mallinckrodt Baker (Paris, KY).
Sodium periodate was obtained from Fisher Scientific (Waltham, MA).
5.2.2 Device fabrication.

An offset T-design with two extra reservoirs was used in the

experiments (see Figure 5.1).9 Silicon templates were fabricated in the BYU Integrated
Microfabrication Lab using standard photolithography techniques to provide elevated channel
features (20 µm tall, 50 µm wide). Microchannel features were hot embossed onto 1.5 mm-thick
PMMA sheets (2 x 5 cm2) for 30 minutes at 138°C. 3-mm thick PMMA sheets (2 x 5 cm2) with
laser-cut reservoirs were thermally bonded as cover plates for 27 minutes at 110°C to enclose the
microfluidic channels.
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Figure 5.1 Schematic of a six-reservoir microfluidic device. 1) Buffer reservoir, 2) injection waste
reservoir, 3) titration reservoir, 4) separation waste reservoir, 5) extra channel for monolith fabrication,
and 6) sample reservoir.

5.2.3 Monolith integration. Monolith fabrication was previously described10 in chapter 4 and
adapted with some changes in the composition of the monolith. Briefly, monolith solution was
made by mixing 0.30 g GMA, 0.10 g EGDMA, 0.20 g Tween-20, 0.20 g cyclohexanol, 0.2 g 1dodecanol and 8 mg DMPA in a glass vial. The solution was vortexed until DMPA was
completely dissolved. Then the solution was immediately loaded into the microfluidic device and
exposed to UV light using a Sun Ray 600 Lamp (Uvitron, West Springfield, MA) for 12 minutes
under a chrome photomask with a 2-mm window. Immediately after polymerization, the
unpolymerized solution was quickly flushed with 2-propanol until the monolith turned white and
then washed with a copious amount of water until 2-propanol was completely removed. The
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monolith columns were dried under vacuum overnight before immobilization of antibody. Figure
5.2 illustrates the schematic of monolith fabrication.

Figure 5.2 Schematic of in-situ monolith fabrication (cross sectional view).

5.2.4 Antibody Immobilization. An immobilization method previously reported11 was
implemented with some modifications (see Figure 5.3). Briefly, the GMA epoxy groups were
hydrolyzed to form diols by incubating the monolith in 0.5 M sulfuric acid at 60 °C for 4 hours.
After flushing the column with water, the monolith was incubated in sodium periodate (1 g/mL
in 90% acetic acid) solution for 4 hours at room temperature in the dark to convert diols into
aldehydes. The aldehyde containing column was then reacted with 5 mg/mL mouse anti-human
IL8 (R&D Systems, McKinley Place, NE) diluted in 0.5X PBS with 100 mg/mL sodium
cyanoboroydride (Sigma, St. Louis, MO) overnight at 4 °C. Fresh antibody solution was pumped
into the column every day for 3 days. The column was washed with 1X PBS buffer to remove
unbound antibodies. The devices were kept at 4 °C and used within 1 week. Figure 5.2 illustrates
the process of antibody immobilization.
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Figure 5.3 Schiff base antibody immobilization on GMA-EGDMA monolithic column.

5.2.5 Sample labeling. Human IL8 protein (Sigma, St. Louis, MO) in a stock solution of 1
mg/mL in carbonate buffer pH 9.2 was labeled with Alexafluor 488 TFP ester (Invitrogen) as
previously reported.9 The dye was first dissolved in dimethyl sulfoxide (Sigma, St. Louis, MO)
to a concentration of 10 mg/mL. 5 µL of the solution was added to 250 µL of IL8 stock solution
and incubated in the dark for 1 hr at room temperature. Excess unconjugated dye was removed
by diafiltration, using an Amicon Ultra-0.5 (Millipore, centrifugal filter (3K MWCO) and 0.5X
PBS, pH 7.4. The amount of filtered IL8 was measured and the sample was stored in the dark at
4 °C until use.
5.2.6 Device Operation. Figure 5.4 illustrates the voltage configuration to manipulate the flow
of sample and solutions in the device. First, the channels were filled with 0.5X PBS. Labeled IL8
was diluted in binding buffer, 0.5X PBS, pH 7.4. For the spiked-saliva sample, the desired IL8
concentration was added to 50% v/v saliva diluted in PBS. Sample was loaded in reservoir 6 and
injected into the column for 5 minutes (see Figure 5.4A). After 5 minutes, the current was turned
off and the sample was allowed to incubate in the column for another 5 minutes.
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Figure 5.4 Device layout and voltage configuration for A) loading, B) washing, and C) elution. 1)
Buffer reservoir, 2) injection waste reservoir, 3) titration reservoir, 4) separation waste reservoir, 5) extra
channel for monolith fabrication, and 6) sample reservoir.

After incubation, the column was thoroughly washed with 0.5X PBS (see Figure 5.3B).
Then, the reservoirs were emptied and cleaned. Elution buffer, 100 mM acetic acid, pH 3, was
loaded into the sample reservoir (6). Buffer (1), titration (3) and separation waste (4) reservoirs
were loaded with 10 mM carbonate-bicarbonate buffer pH 10. The rest of the reservoirs were
loaded with 0.5X PBS. Fluorescence was detected using a photomultiplier tube and the
electrochromatogram was recorded using LabView.
5.2.5 Saliva processing. Saliva samples were obtained by drooling and collected in cold, sterile
conical tubes. About 5 mL of saliva was collected and immediately centrifuged at 14 000 rpm for
10 minutes at room temperature to remove debris. The saliva was immediately frozen unless
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used immediately. Saliva was spiked with fluorescently labeled IL8 immediately before use and
then vortexed prior to loading in the reservoir.
5.3 RESULTS AND DISCUSSION
Monolithic columns were successfully integrated in PMMA microfluidic devices. Figure
5.5A shows a photomicrograph of an integrated monolithic column showing a continuous
column and Figure 5.5B shows a porous monolith with high surface area imaged using an
electron microscope (Philips FEI XL30 ESEM).

Figure 5.5 A) Photomicrograph of a continuous monolithic column in a PMMA device, B) SEM
image of a monolith column showing a high surface area, porous monolith.

Monolithic columns were fabricated in-situ without prior modification of PMMA. The
methacrylate on the surface of PMMA was compatible with the GMA-EGDMA monolith and
showed mechanical stability over several runs. However, one of the problems encountered was
bubble formation when the channels were being filled with buffer. Using pressure to push the
bubbles out of the column can solve this problem but sometimes resulted in delaminated
microfluidic devices. Bubbles also formed when voltage was continuously applied longer than
10 minutes; for this reason, 5-minute injection and lower voltages were used.
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Immobilization of mouse anti-IL8 was verified by probing the column with an antimouse secondary antibody conjugated to an infrared fluorescent dye. The column was then
scanned for fluorescence using a LI-COR Odyssey near IR fluorescence scanner (Lincoln, NE).
Figure 5.6A shows the column modified with mouse anti-IL8 probed with anti-mouse secondary
antibody fluorescing indicating the presence of immobilized antibodies, while the column
blocked with non-fat dry milk only showed no fluorescence (see Figure 5.6B).

Figure 5.6 LI-COR image of monolith columns modified with A) anti-human IL8 and B) non-fat
dry milk. Green color indicates presence of anti-human IL8.

The binding of the immobilized antibodies to IL8 was tested by electrochromatography.
Low pH quenches the fluorescence of Alexa Flour so a high pH buffer was used to titrate the
eluted stream to bring back fluorescence, a technique previously described by Wang et al.12
Figure 5.7 shows the electrochromatogram of elution of IL8 extracted from buffer. A single
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sharp peak at ~100 s was observed when Alexafluor dye was loaded onto the column (see Figure
5.7A). An extra peak that eluted at ~150 s was obtained when labeled IL8 was loaded onto the
column (see Figure 5.7B) and the intensity of this peak increased when the IL8 concentration
was increased from 1 ng/mL to 5 ng/mL (see Figure 5.7C).

Figure 5.7 Affinity electrochromatograms of IL8 in buffer. A) Dye, B) 1 ng/mL IL8, and C) 5 ng/ mL.

I then tested the extraction of IL8 from 50% saliva. 100% saliva was viscous, so 50%
saliva in buffer was used. A similar electrochromatogram was observed with IL8-spiked saliva
(see Figure 5.8B-C). However, no IL8 peak was observed at IL8 concentrations lower than 10
ng/mL, which may be due to interference by other salivary proteins. The electrochromatogram of
labeled unspiked saliva also only showed a peak that corresponded to the dye (compare Figure
5.8A with Figure 5.7A). The absence of an IL8 peak may be because the saliva from the healthy
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donor had low IL8 that was not detectable using this method. Furthermore, using the same
column for more than three complete runs failed to extract of IL8, which may be due to the loss
of activity of the antibodies after exposure to extreme pH conditions. For point-of-care
application, devices are meant for one time use. Loss of activity would be a problem if the
column were to be used multiple times like in research settings or optimization processes. For
multiple uses, either a competitor to elute bound proteins or a different antibody with good
stability at extreme pH conditions would be a good alternative.

Figure 5.8 Affinity electrochromatograms of IL8-spiked saliva. A) Labeled saliva and B-C) 10 ng/mL
IL8 spiked saliva.

5.4 CONCLUSIONS
I have demonstrated a working microfluidic device with integrated IL8 monolith affinity
column. The columns were easily fabricated in-situ without the need to modify the surface of
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PMMA prior to fabrication. I have also successfully extracted, eluted, and detected human IL8
from buffer and from spiked saliva at concentrations as low as 1 ng/mL and 10 ng/mL,
respectively. Clinically relevant concentrations of IL8 were reported to be in the pg/mL range so
there is a need to improve the limit of detection. Increasing the column volume and surface area
would increase loading capacity. Forming a monolith with smaller nodules that still maintains
low backpressure could increase surface area. Furthermore, increasing the density of antibody in
the column would help increase the loading capacity. Increasing the antibody concentration
during surface attachment or optimizing the immobilization conditions such as temperature and
time could improve the density of the immobilized antibody. Therefore, further optimization of
the immobilization procedure should be conducted. Depleting abundant proteins to improve
detection could also help to better detection of low abundance IL8 in saliva.
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CHAPTER 6. SUMMARY AND FUTURE WORK

6.1 SUMMARY

I have demonstrated fabrication of PMMA microfluidic devices and developed
immunoassays for detecting two potential cancer biomarkers, thymidine kinase 1 (TK1) and
interleukin 8 (IL8).
1% w/v methylcellulose in buffer acts as a dynamic coating and sieving matrix and
demonstrated a simple yet effective method to separate large proteins such as IgG and its
immune complex. Other dynamic coatings could be explored to improve separation efficiency of
the antigen-antibody complex from free antibody. The struggle to detect endogenous TK1 in
serum was determined to be due to the inability of the novel mouse anti-TK1 to form a complex
with TK1 under the conditions used in the experiments. This finding can be applied to future
assay development by using the commercial rabbit anti-TK1 antibody. Immunoassays depend on
the ability of the antibody to specifically determine the target antigen. The ability of the antibody
to bind the target antigen must be first established or any attempt to optimize other parameters
such as pH, ionic strength, etc. would be futile, as was the case in my attempt to detect
endogenous TK1 prior to characterization of the novel mouse anti-TK1.
I have also described a method to batch process multiple monolith formulations using
SEM that led to faster optimization of monolithic columns for microfluidic devices. Batch
processing made it possible to qualitatively assess the effect of Tween-20 on the morphology of
the monolith column before its integration on-chip. This saved time and resources by not using
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devices for early stage monolith optimization. I have integrated monolithic columns in PMMA
devices and successfully immobilized active antibodies for affinity extraction of interleukin 8
from buffer and saliva. The lowest IL8 concentration detected was 1 ng/mL in buffer and
10 ng/mL in spiked saliva. The higher detection limit in spiked saliva may be due to the
interference by other high abundance proteins. Protein depletion described in Chapter 3 could be
used for testing endogenous IL8 to further this work.
6.2 FUTURE WORK
6.2.1 Integrated blood plasma separation and protein immunodepletion for immune
complex detection in microfluidics.
Blood analysis often requires removal of interfering cells such as red blood cells, white
blood cells, and platelets. Blood is usually drawn and processed using conventional methods
such as centrifugation to extract plasma for analysis. Another method used to remove cells is
through cell lysis. However, this technique results in release of proteins and nucleic acids into
the plasma thus contaminating it. Integration of plasma isolation processes on chip would
decrease sample contamination and sample preparation time.
Several groups have utilized the Zweifach-Fung effect or bifurcation law to isolate
plasma from blood cells in microfluidic devices.1, 2 The bifurcation law describes that a particle,
in this case blood cells, at a bifurcation region has a tendency to move towards a channel with
higher flow rate, leaving very few cells flowing into the lower flow rate channel.2 Obtaining cellfree plasma is affected by the geometry of the bifurcating channels.3
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Plasma is replete with proteins that can interfere with immunoassays. As described in
Chapter 2, depletion of immunoglobulin and serum albumin can enrich low-abundance protein
biomarkers. Even though ammonium sulfate precipitation is a cheap and effective method to
enrich low-abundance proteins it requires a desalting step to make the protein depleted sample
compatible with microchip electrophoresis. For this reason, an immunodepletion monolith
column would be more suitable. Figure 6.1 shows the schematic of a microfluidic device with
the capability to isolate plasma analyze protein markers by immunoaffinity microchip
electrophoresis. Blood can be loaded into the device using integrated pumps.4 At the bifurcation
point, the plasma will be collected in the plasma reservoir and the blood cells will exit the other
channel. Valves will also be used to prevent sample leakage during loading and microchip
electrophoresis. The collected plasma will then be depleted of immunoglobulin and albumin for
better detection of low-abundance markers. The plasma sample can be loaded into the column by
pumping. The serpentine design of the reaction channel will enhance mixing of fluorescently
tagged antibody with the antigen, and hence should decrease reaction time. Gated injection could
be used to load a larger sample volume for detection of low-abundance markers.
This integrated device will eliminate the need to process the blood off-chip thus
decreasing sample analysis time and contamination. A multilayer device could be designed for
parallel analysis of biomarkers without increasing the footprint of the device.
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Figure 6.1 Microchip device with integrated plasma extraction module.

6.2.2 Microfluidic neutrophil isolation and procalcitonin detection for sepsis diagnosis
Sepsis is a serious complication caused by bacteria or other microbial organisms and is
the leading cause of mortality in critically ill patients.5 Delay in diagnosis and immediate therapy
results in higher mortality.6 The gold standard for sepsis diagnosis is the broth culture method
but this can take as long as 24 hours to arrive at a definitive diagnosis.5 There is a need to
accurately determine in timely and cost-effective manner if the observed inflammatory response
is due to bacterial infection. Thus, interest increased in sepsis biomarkers that can provide
additional information from already established clinical assessments and investigation.6 Several
biomarkers are routinely measured in hospital laboratories such as C-reactive protein and
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cytokines (i.e., interleukins 6 and 8, and tumor necrosis factor). However these markers are also
elevated in other chronic inflammatory conditions.6, 7
Procalcitonin, a precursor of the hormone calcitonin, was observed to increase from its
normal level (<0.1 ng/mL) at 4 hours after the onset of infection, peaking between 8 and 24
hours.5 Another marker is CD64, a glycoprotein expressed on the neutrophil membrane, which
was reported to be upregulated in newborn sepsis.7,8 Flow cytometry analysis of cell surface
markers is a fast and efficient method, but flow cytometry is expensive, bulky and requires
special training.
Integrated microfluidic devices that could analyze both CD64 and serum proteins could
address the shortcomings of traditional sepsis diagnostics. Figure 6.2 illustrates a modification of
Figure 6.1 that would selectively isolate neutrophils from other blood cells to measure CD64 and
analyze protein sepsis markers.
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Figure 6.2 CD64+ neutrophil and procalcitonin detection for sepsis diagnosis in microfluidic
devices.

Neutrophils can be selectively isolated from other blood cells by using affinity flow
fractionation described by Bose et al.9 They immobilized P-selectin, a protein that specifically
interacts with neutrophils, in asymmetric patterns on the surface of a microfluidic channel. When
the neutrophil attached to P-selectin, the cell was displaced laterally into the buffer stream and
could reattach to the molecular marker. When it reached the non-patterned region it was quickly
eluted. Using this technique they were able to obtain intact neutrophils with >92% purity.
Isolated neutrophils will be drawn to the channel with immunoaffinity posts that will selectively
bind for CD64+ cells. A similar approach to that used for detecting circulating tumor cells in
polymeric microfluidic devices will be used in the cell capture module.10 Adding this cell capture
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module will eliminate the need for flow cytometry detection of CD64+ neutrophils. The isolated
plasma will be processed and probed for procalcitonin as described in section 6.2.1. The
combined cell surface marker and protein biomarker analysis may facilitate faster differential
diagnosis of sepsis, so proper therapy can be immediately administered.
Combining cell flow fractionation, target cell capture, protein depletion, and
immunoaffinity microchip electrophoresis in microfluidic devices would allow analysis of whole
blood without off-chip preparation. The aim is to be able to analyze a ten microliter volume to
make this testing compatible with infants and older patients. The ability to analyze small sample
volumes may lead to a shorter analysis time that is beneficial for time-sensitive conditions. The
ligands used for target marker identification can be changed to fit the needed tests thus making
these devices applicable for immunoassays of other disease markers.
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